BRITISH NUCLEAR MEDICINE SOCIETY
ANNUAL MEETING
21 - 24 APRIL 2013
Brighton Conference Centre

www.bnms.org.uk
A maximum of 15 CME/CPD credits have been awarded to the meeting
Contents

2
British Nuclear Medicine Society

3
General information

4
Social events

5
At a glance programme

9
Programme
Sunday – Boot Camp
Day 1 - Monday 22 April
Day 2 - Tuesday 23 April
Day 3 - Wednesday 24 April

19
Poster Presentations

24
Finding your way to the Brighton Centre

25
Finding your way around Brighton

26
Exhibiting companies and Exhibition plan

27
Exhibiting companies

31
BNMS membership application form

32
Methods of membership payment
**Scientific Committee**

Dr J Bomanji (Chair)
Ms S Allen
Prof A Al-Nahhas
Dr P Arumugam
Dr A Bolster
Mrs J Croasdale
Dr R Ganatra
Dr S Hughes
Dr P Kemp
Mr P Maltby
Dr C Marshall
Dr P Ryan (Poster Chair)
Mr P Facey
Mrs S Farrell
Ms C Lory

**2012/13 Council members**

Dr JB Neilly President
Prof AC Perkins Immediate past-President
Ms S Allen Hon Secretary
Prof S Vinjamuri Hon Treasurer
Dr J Birchall Trustee
Dr G Flux Trustee
Dr R Graham Trustee
Ms C Greaves Trustee
Dr D Green Trustee
Dr M Hall Trustee
Mr P Maltby Trustee
Dr P Ryan Trustee
Dr P Arumugam, BNCS President
Mr P Facey Clinical Practitioner
Mrs S Farrell Clinical Practitioner
Dr A Corrigan Medical Trainee
Dr J Ballinger NMC News & Views
Mr M Ward NM Industry Association
Ms C Lory Nurse
Mrs H Scicluna Nurse
to be appointed Patient Representative
Mrs J Croasdale Radiopharmaceutical Sciences
Dr J Bomanji Scientific Committee

---

**Conference organisation**

Scientific Chair Dr J Bomanji
Poster Session Organiser Dr P Ryan
Judging Panel Dr J Bomanji
YIP judging: Dr B Neilly, Dr M Hall
Exhibition Organiser Mrs S Hatchard
Conference Secretariat Ms S Weston
Ms N Fenning

---

**Society membership**

Membership of the British Nuclear Medicine Society is open to those who have a substantial interest and involvement in the development and provision of Nuclear Medicine services. The Society exists to further the professional, scientific and clinical interests of members and to support the development of Nuclear Medicine for the benefit of patients.

**Subscription rates**

<table>
<thead>
<tr>
<th>Membership Type</th>
<th>UK</th>
<th>Overseas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Member</td>
<td>£132</td>
<td>£172</td>
</tr>
<tr>
<td>Full Member-reduced</td>
<td>£108</td>
<td>£122</td>
</tr>
<tr>
<td>Associate Member</td>
<td>£60</td>
<td>£97</td>
</tr>
</tbody>
</table>

An application form for membership can be found at the back of the programme. Further details are available at the Conference Registration Desk or by visiting our web site (www.bnms.org.uk)

---

**Conference registration**

On-line Registration only:
www.bnms.org.uk
Tel: 020 8676 7864
Fax: 020 8676 8417
Email: office@bnms.org.uk

---

---

---
General Information

AV Centre and Speaker preview
1st Floor

BNMS stand and Internet access
Exhibition Hall - stand No.29

BOOT CAMP - Sunday afternoon
Our Bootcamp this year is covering all aspects of PET-MR to include setting up a PET-MR service, clinical applications, Do’s and don’ts for Clinical Practitioners and Research.

A fee of £25 for members (£35 non-members) is being charged to include lunch. A maximum of 3 CME/CPD credits have been awarded to Boot Camp.

Catering
Coffee and Tea in Exhibition hall. See detailed programme.

Tea and Coffee will be available free of charge in the exhibition area.

09.00 – 17.00 Coffee shop
Tea/coffee/soft drinks, crisps and confectionery. Selection of sandwiches, baguettes, cakes and pastries.

Wednesday Complimentary Buffet lunch

CME/CPD
A maximum of 15 CME/CPD credits have been awarded to this meeting. Delegates can only record the actual number of hours attended for CME/CPD purposes.

Please note: CME/CPD certificates will be available for collection at the end of each day or on Wednesday for those attending all three days of the meeting.

Commercial Exhibition - 1st Floor

Monday 09.00 – 17.30pm
Tuesday 09.00 – 17.30pm
Wednesday 09.00 - 14.00pm

Emergency contact details
The emergency contact telephone number for delegates attending the conference is 01273 290 131

Hotel accommodation
See hotel listing and booking form on the BNMS website www.bnms.org.uk or contact Reservation Highway:
Tel 01423 525 577

Internet access
Free internet access is available for delegates in the Exhibition Hall on the BNMS stand.

Lanyards
Kindly sponsored by Siemens

Pads
Kindly sponsored by InHealth Group

Pens
Kindly sponsored by Sirtex

Pre-registration
‘Meet and Greet’ Reception
Sunday 21 April 5.30 – 7.00pm
Foyer, Brighton Convention Centre.

Prizes for proffered papers and posters

Young Investigator’s Prize
£500 awarded by BNMS.

Clinical Practitioner prizes funded by an Educational Grant from Covidien
1st Oral £300
1st Poster £300

Oral paper prizes awarded by Philips
1st £300
2nd £150
3rd £50

Oral Multimodality prize awarded by Hermes £350

Poster prizes awarded by GE Healthcare
1st £300
2nd £150
3rd £50

Poster Multimodality prize awarded by Hermes £250

Radiopharmacy a new prize of £250 for 2013 awarded by IBA Molecular UK

Student Prize
1st £100 and free registration awarded by BNMS on abstract submission alone
2nd £75
3rd £50

Poster display and Judging-Exhibition Hall
Monday Posters P1 - P38 also CP1 - CP9
Tuesday Posters P39 - P78

Registration
08.30 daily. Alternatively pre-register at the ‘Meet and Greet’ Reception on Sunday 5.30 - 7pm.

Special interest groups

Monday
BNMS Clinical Scientists Forum
Syndicate 1 & 2 13.15 – 13.45

BNMS Nurses AGM
Syndicate 3 & 4 13.15 – 13.45

Tuesday
BNMS Medics Forum
Auditorium 2 13.15 – 13.45

SpR Forum
Meeting Room 1
Ground Floor 13.15 – 13.45

BNMS Radiopharmaceutical Sciences AGM
Syndicate 3 & 4 13.15 – 13.45

15.30 UK PET Physics Group
Radiation Protection in PET – in principle and in practice

BNMS Members’ AGM
Auditorium 2 17.15 – 18.00

Wednesday
08.30 Nuclear Medicine Therapy Group
(Molecular Radiotherapy)
Molecular therapy in the UK: toward evidence-based harmonisation
Social Events

‘Meet & Greet’ Reception
Sunday 21 April 5.30 pm – 7.00 pm
Conference Centre Foyer

BNMS Cocktail Party
Monday 22 April 6.00 pm – 8.00 pm
Held in The Restaurant, 3rd Floor, Conference Centre

Charity Fun Run
Tuesday 23 April 7.30 am
Meet on the Lower Promenade opposite the Brighton Centre

BNMS Awards Ceremony and Dinner
Tuesday 23 April 7.30 pm to midnight
Regency Ballroom, Hilton Brighton Metropole Hotel

CHARITY FUN RUN along the sea front - all proceeds going to AUTISM SUSSEX - this is going to be a 3 kilometre run. Donations gratefully accepted.

Autism Sussex is an independent, not for profit organisation and registered charity, whose aim is to provide a range of opportunities for children, young people and adults with autistic spectrum conditions and/or Asperger syndrome.
## At a glance programme

**SUNDAY 21 APRIL AUDITORIUM 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.15</td>
<td>BOOT CAMP - PET/MR Complimentary Buffet lunch</td>
</tr>
<tr>
<td>14.00</td>
<td>Setting up a PET/MR service</td>
</tr>
<tr>
<td>14.20</td>
<td>Basic Principals of MRI: Physics made easy</td>
</tr>
<tr>
<td>14.40</td>
<td>MRI Functional imaging (T1, T2, DWI etc): What does it mean?</td>
</tr>
<tr>
<td>15.00</td>
<td>Clinical applications of PET/MRI (Cardiac/Vascular)</td>
</tr>
<tr>
<td>15.30</td>
<td>Tea</td>
</tr>
<tr>
<td>16.00</td>
<td>Clinical applications of PET/MRI (Lymphoma/ Head &amp; neck)</td>
</tr>
<tr>
<td>16.20</td>
<td>Clinical Practitioner Viewpoint: Do’s and Don’ts to maintain technical quality</td>
</tr>
<tr>
<td>16.40</td>
<td>Clinical applications of PET/MRI (Gynaec/GIT)</td>
</tr>
<tr>
<td>17.00</td>
<td>PET/MR Research Programme</td>
</tr>
</tbody>
</table>
**MONDAY 22 APRIL AUDITORIUM 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>INAUGURATION</td>
</tr>
<tr>
<td>09.10</td>
<td>BONE IMAGING THE SPINE: WHEN TO SPECT-CT, PET-CT OR PET-MRI</td>
</tr>
<tr>
<td>09.30</td>
<td>IMAGING BONE METASTASES: SPECT &amp; PET TRACERS</td>
</tr>
<tr>
<td>09.50</td>
<td>RADIONUCLIDE IMAGING IN SPORTS INJURIES</td>
</tr>
<tr>
<td>10.10</td>
<td>DO’S &amp; DON’TS TO MAINTAIN HIGH QUALITY IMAGING: CLINICAL PRACTITIONER’S VIEW</td>
</tr>
<tr>
<td>10.30</td>
<td>TECHNICAL ADVANCES IN BONE IMAGING: EMPHASIS ON RESOLUTION RECOVERY</td>
</tr>
<tr>
<td>10.50</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>11.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>11.30</td>
<td>BRAIN</td>
</tr>
<tr>
<td>11.50</td>
<td>PET-CT IN ADDICTION</td>
</tr>
<tr>
<td>12.10</td>
<td>ADVANCES IN BRAIN PET &amp; SPECT IMAGING: EMPHASIS ON DEMENTIA</td>
</tr>
<tr>
<td>12.30</td>
<td>TECHNICAL ADVANCES IN BRAIN IMAGING-SOFTWARE</td>
</tr>
<tr>
<td>12.50</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>13.00</td>
<td>LUNCH, Poster Session &amp; Meet Industry</td>
</tr>
<tr>
<td>13.15</td>
<td>NUCLEAR MEDICINE IN EUROPE &amp; ASIA PACIFIC</td>
</tr>
<tr>
<td>14.00</td>
<td>ROLE OF PET-CT IN ESTABLISHED AND EMERGING CLINICAL APPLICATIONS: THE DANISH EXPERIENCE</td>
</tr>
<tr>
<td>14.30</td>
<td>ROLE OF NUCLEAR MEDICINE IN IMAGE-GUIDED SURGERY TODAY AND PERSPECTIVES AHEAD</td>
</tr>
<tr>
<td>15.00</td>
<td>AFFORDABLE NUCLEAR MEDICINE: NEW TRACERS FROM INDIA</td>
</tr>
<tr>
<td>15.30</td>
<td>NUCLEAR MEDICINE IN MIDDLE EAST</td>
</tr>
<tr>
<td>16.00</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>16.10</td>
<td>TEA and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>16.30</td>
<td>ENDOCRINE &amp; EDUCATION</td>
</tr>
<tr>
<td>17.00</td>
<td>THE SCIENCE AND TECHNOLOGY FACILITIES COUNCIL AND NUCLEAR MEDICINE</td>
</tr>
<tr>
<td>17.20</td>
<td>ROLE OF RADIONUCLIDE IMAGING IN THYROID &amp; PARATHYROID SURGERY</td>
</tr>
<tr>
<td>17.40</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>18.00</td>
<td>AGMs/Special interest group forums: lunch time meetings</td>
</tr>
</tbody>
</table>

**MONDAY 22 APRIL SYNDICATE 1 & 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td>ENDOCRINE AND MISCELLANEOUS</td>
</tr>
<tr>
<td>09.15</td>
<td>Proffered papers</td>
</tr>
<tr>
<td>09.45</td>
<td>WALES RESEARCH AND DIAGNOSTIC POSITRON EMISSION TOMOGRAPHY IMAGING CENTRE - THE STORY SO FAR</td>
</tr>
<tr>
<td>10.15</td>
<td>THE FIRST TWO YEARS OF PET-CT – OUR CLINICAL EXPERIENCE</td>
</tr>
<tr>
<td>10.45</td>
<td>PET-CT IN LUNG CANCER– EVERYTHING YOU NEED TO KNOW</td>
</tr>
<tr>
<td>11.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>11.30</td>
<td>BONE AND LUNG Proffered papers</td>
</tr>
<tr>
<td>11.15</td>
<td>RADIOTHERAPY PLANNING IN PET-CT - FIRST CONTACT</td>
</tr>
<tr>
<td>11.45</td>
<td>NuDOTATE THERAPY – OUR EXPERIENCE</td>
</tr>
<tr>
<td>12.15</td>
<td>NUCLEAR MEDICINE MOVES INTO INTERVENTION RADIOLGY - THE ROLE OF THE CLINICAL PRACTITIONER IN SELECTIVE INTERNAL RADIATION THERAPY (SIRT)</td>
</tr>
<tr>
<td>12.30</td>
<td>TECHNICAL ADVANCES IN BRAIN IMAGING-SOFTWARE</td>
</tr>
<tr>
<td>12.45</td>
<td>LUNCH, Poster Session &amp; Meet Industry</td>
</tr>
<tr>
<td>13.00</td>
<td>LUNCH, Poster Session &amp; Meet Industry</td>
</tr>
<tr>
<td>14.00</td>
<td>NUCLEAR MEDICINE IN EUROPE &amp; ASIA PACIFIC</td>
</tr>
<tr>
<td>14.00</td>
<td>Proffered papers</td>
</tr>
<tr>
<td>14.15</td>
<td>INDUSTRY DEMONSTRATIONS</td>
</tr>
<tr>
<td>15.00</td>
<td>TEA and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>15.30</td>
<td>TEA and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>16.00</td>
<td>GENERAL NUCLEAR MEDICINE 1</td>
</tr>
<tr>
<td>16.00</td>
<td>SeH:CAT: NICE GUIDELINES, AND FUTURE</td>
</tr>
<tr>
<td>16.20</td>
<td>CHANGING LANDSCAPE IN PAEDIATRIC IMAGING</td>
</tr>
<tr>
<td>16.40</td>
<td>HOMEWORK FOR WRITING A BUSINESS PLAN: SPECT/CT SERVICE</td>
</tr>
<tr>
<td>17.00</td>
<td>BUSINESS PLAN FOR A PET-CT SERVICE</td>
</tr>
<tr>
<td>17.20</td>
<td>V/Q SPECT</td>
</tr>
<tr>
<td>17.40</td>
<td>PANEL DISCUSSION</td>
</tr>
</tbody>
</table>

**MONDAY 22 APRIL SYNDICATE 3 & 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td>ENDOCRINE AND MISCELLANEOUS</td>
</tr>
<tr>
<td>09.45</td>
<td>WALES RESEARCH AND DIAGNOSTIC POSITRON EMISSION TOMOGRAPHY IMAGING CENTRE - THE STORY SO FAR</td>
</tr>
<tr>
<td>10.15</td>
<td>THE FIRST TWO YEARS OF PET-CT – OUR CLINICAL EXPERIENCE</td>
</tr>
<tr>
<td>10.45</td>
<td>PET-CT IN LUNG CANCER– EVERYTHING YOU NEED TO KNOW</td>
</tr>
<tr>
<td>11.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>11.30</td>
<td>BONE AND LUNG Proffered papers</td>
</tr>
<tr>
<td>11.15</td>
<td>RADIOTHERAPY PLANNING IN PET-CT - FIRST CONTACT</td>
</tr>
<tr>
<td>11.45</td>
<td>NuDOTATE THERAPY – OUR EXPERIENCE</td>
</tr>
<tr>
<td>12.15</td>
<td>NUCLEAR MEDICINE MOVES INTO INTERVENTION RADIOLGY - THE ROLE OF THE CLINICAL PRACTITIONER IN SELECTIVE INTERNAL RADIATION THERAPY (SIRT)</td>
</tr>
<tr>
<td>12.30</td>
<td>TECHNICAL ADVANCES IN BRAIN IMAGING-SOFTWARE</td>
</tr>
<tr>
<td>12.45</td>
<td>LUNCH, Poster Session &amp; Meet Industry</td>
</tr>
<tr>
<td>13.00</td>
<td>LUNCH, Poster Session &amp; Meet Industry</td>
</tr>
<tr>
<td>14.00</td>
<td>NUCLEAR MEDICINE IN EUROPE &amp; ASIA PACIFIC</td>
</tr>
<tr>
<td>14.00</td>
<td>Proffered papers</td>
</tr>
<tr>
<td>14.15</td>
<td>INDUSTRY DEMONSTRATIONS</td>
</tr>
<tr>
<td>15.00</td>
<td>TEA and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>15.30</td>
<td>TEA and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>16.00</td>
<td>GENERAL NUCLEAR MEDICINE 1</td>
</tr>
<tr>
<td>16.00</td>
<td>SeH:CAT: NICE GUIDELINES, AND FUTURE</td>
</tr>
<tr>
<td>16.20</td>
<td>CHANGING LANDSCAPE IN PAEDIATRIC IMAGING</td>
</tr>
<tr>
<td>16.40</td>
<td>HOMEWORK FOR WRITING A BUSINESS PLAN: SPECT/CT SERVICE</td>
</tr>
<tr>
<td>17.00</td>
<td>BUSINESS PLAN FOR A PET-CT SERVICE</td>
</tr>
<tr>
<td>17.20</td>
<td>V/Q SPECT</td>
</tr>
<tr>
<td>17.40</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>TIME</td>
<td>SYNDICATE 1 &amp; 2</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------</td>
</tr>
<tr>
<td>09.00</td>
<td>CARDIOLOGY I</td>
</tr>
<tr>
<td>IMPACT OF NICE GUIDELINES ON MPS IMAGING</td>
<td>UPDATE ON NEW NON-PET TRACERS COMING TO MARKET</td>
</tr>
<tr>
<td>09.30</td>
<td>MPS MORPHING WITH COMPETING MODALITIES</td>
</tr>
<tr>
<td>09.50</td>
<td>EMERGING APPLICATIONS: FOCUS ON SARCOIDOSIS &amp; AMYLOIDOSIS</td>
</tr>
<tr>
<td>10.10</td>
<td>TECHNICAL ADVANCES: NEW CAMERAS &amp; SOFTWARE FOR MYOCARDIAL PERFUSION &amp; FUNCTION</td>
</tr>
<tr>
<td>10.30</td>
<td>DO’S &amp; DON’T S TO MAINTAIN HIGH QUALITY IMAGING: CLINICAL PRACTITIONER’S VIEW</td>
</tr>
<tr>
<td>10.50</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>10.45</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>11.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>11.00</td>
<td>Proffered Papers</td>
</tr>
<tr>
<td>11.30</td>
<td>ONCOCOLOGY I</td>
</tr>
<tr>
<td>PET-CT: WHERE ARE WE IN CURRENT GUIDELINES IN CANCER IMAGING?</td>
<td></td>
</tr>
<tr>
<td>11.50</td>
<td>PET-CT IN GynaECOLOGICAL MALIGNANCY</td>
</tr>
<tr>
<td>12.10</td>
<td>PET-CT/MRI IN PROSTATE CANCER</td>
</tr>
<tr>
<td>12.30</td>
<td>PET-CT IN PARANEOPlastic SYNDROME</td>
</tr>
<tr>
<td>12.50</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch and Meet Industry</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch and Meet Industry</td>
</tr>
<tr>
<td>13.15</td>
<td>Update on Clinical Pharmaceutical Sciences STP course as part of Modernising Scientific Careers</td>
</tr>
<tr>
<td>14.00</td>
<td>ANNUAL LECTURE: ADVANCES IN HIGH RESOLUTION MULTI-MODALITY IMAGING: FROM PHYSICIST TO PHYSICIAN</td>
</tr>
<tr>
<td>15.00</td>
<td>TEA, poster viewing &amp; meet industry</td>
</tr>
<tr>
<td>15.15</td>
<td>BNMS Clinical Practitioners AGM - Syndicate 1 &amp; 2</td>
</tr>
<tr>
<td>15.15</td>
<td>Medics Forum - Auditorium 2</td>
</tr>
<tr>
<td>15.15</td>
<td>SpR Forum - Meeting Room 1, Ground Floor</td>
</tr>
<tr>
<td>15.15</td>
<td>BNMS Radiopharmaceutical Sciences Group AGM - Syndicate 3 &amp; 4</td>
</tr>
<tr>
<td>15.30</td>
<td>UK PET Physics Group – Auditorium 2</td>
</tr>
</tbody>
</table>

**TUESDAY 23 APRIL AUDITORIUM 2**

**TUESDAY 23 APRIL SYNDICATE 1 & 2**

**TUESDAY 23 APRIL SYNDICATE 3 & 4**
## At a glance programme

### WEDNESDAY 24 APRIL AUDITORIUM 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>GENERAL NUCLEAR MEDICINE II</td>
</tr>
<tr>
<td></td>
<td>CHANGING LANDSCAPE FOR NUCLEAR MEDICINE TRAINEES: PREPARE YOURSELF</td>
</tr>
<tr>
<td>08.50</td>
<td>THE NEXT GENERATION OF MEDICS: GUIDANCE FROM THE SNMS PRESIDENT</td>
</tr>
<tr>
<td>09.10</td>
<td>SENTINEL NODE IMAGING: CURRENT STATUS &amp; FUTURE DIRECTIONS</td>
</tr>
<tr>
<td>09.30</td>
<td>LIVER TRANSPLANT IMAGING</td>
</tr>
<tr>
<td>09.50</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>10.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>10.30</td>
<td>ONCOLOGY II</td>
</tr>
<tr>
<td></td>
<td>CURRENT PRACTICE &amp; CONTROVERSIES IN RADIONUCLIDE THERAPY FOR NETS</td>
</tr>
<tr>
<td>10.50</td>
<td>SELECTION &amp; FOLLOW UP OF PATIENTS WITH NETS</td>
</tr>
<tr>
<td>11.10</td>
<td>CURRENT PRACTICE &amp; CONTROVERSIES IN RADIONUCLIDE THERAPY FOR DTC</td>
</tr>
<tr>
<td>11.30</td>
<td>MANAGEMENT STATERGY IN IODINE-NEGATIVE/THYROID-GLOBULIN-POSITIVE</td>
</tr>
<tr>
<td></td>
<td>PATIENTS</td>
</tr>
<tr>
<td>11.50</td>
<td>DO’S &amp; DON’TS TO MAINTAIN A HIGH QUALITY THERAPY UNIT-PHYSICISTS VIEW</td>
</tr>
<tr>
<td>12.15</td>
<td>PRIZE PRESENTATION (Auditorium 2)</td>
</tr>
<tr>
<td>12.30</td>
<td>HIGHLIGHTS LECTURE (Auditorium 2)</td>
</tr>
<tr>
<td>13.15</td>
<td>COMPLIMENTARY LUNCH AND CLOSE OF MEETING</td>
</tr>
</tbody>
</table>

### WEDNESDAY 24 APRIL SYNDICATE 1 & 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45</td>
<td>ONCOLOGY III</td>
</tr>
<tr>
<td></td>
<td>Proffered Papers</td>
</tr>
<tr>
<td>10.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
<tr>
<td>10.30</td>
<td>ONCOLOGY IV</td>
</tr>
<tr>
<td></td>
<td>Proffered Papers</td>
</tr>
</tbody>
</table>

### WEDNESDAY 24 APRIL SYNDICATE 3 & 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Nuclear Medicine Therapy Group (Molecular Radiotherapy)</td>
</tr>
<tr>
<td></td>
<td>SPECIAL INTEREST GROUP</td>
</tr>
<tr>
<td></td>
<td>Molecular radiotherapy in the UK: Toward evidence-based harmonization</td>
</tr>
<tr>
<td>10.00</td>
<td>PHYSICS II</td>
</tr>
<tr>
<td></td>
<td>Proffered Papers</td>
</tr>
<tr>
<td>10.45</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
</tr>
</tbody>
</table>
SUNDAY 21 AUDITORIUM 2

13.15  BOOT CAMP
Complimentary buffet lunch

14.00  Setting up a PET-MR Service
Dr Jamshed Bomanji
Institute of Nuclear Medicine, UCLH

14.20  Basic principals of MRI: Physics made easy
Mr Peter Lally
Institute of Nuclear Medicine, UCLH

14.40  MRI Function Imaging (T1, T2, DWI etc.): What does it mean?
Dr Shonit Punwani
University College Hospital, London

15.00  Clinical applications of PET-MRI (Cardiac/Vascular)
Dr Leon Menezes
Institute of Nuclear Medicine, UCLH

15.30  Tea

16.00  Clinical applications of PET-MRI (Lymphoma/Head & Neck)
Dr Irfan Kayani
Institute of Nuclear Medicine, UCLH

16.20  Clinical Practitioner viewpoint: Do’s and Don’ts to maintain technical Quality
Celia O’Meara
Institute of Nuclear Medicine, UCLH

16.40  Clinical applications of PET-MRI (Gynae/GIT)
Dr Rizwan Syed
Institute of Nuclear Medicine, UCLH

MONDAY 22 AUDITORIUM 2

09.00  Inauguration
Dr Brian Neilly – BNMS President and
Prof Alan Perkins, Immediate Past President

09.10  Imaging the Spine: When to SPECT/CT, PET-CT or PET/MRI
Dr Rizwan Syed
Institute of Nuclear Medicine, UCLH

09.30  Imaging Bone Metastases: SPECT and PET Tracers
Prof Gary Cook
King’s College London

09.50  Radionuclide Imaging in Sports Injuries
Dr Ranju Dhawan
Imperial College Healthcare NHS Trust

10.10  Do’s and Don’ts to maintain high quality imaging: Clinical Practitioner’s View
Mrs Ann French
Glasgow Royal Infirmary

10.30  Technical advances in bone imaging: Emphasis on resolution recovery
Dr Matt Aldridge,
Institute of Nuclear Medicine, London

10.50  PANEL DISCUSSION

11.00  COFFEE and Meet Industry in the Exhibition Hall

BRAIN
Chairs: Dr Kevin Bradley, Dr Simon Hughes

SPECT and PET in Epilepsy
Dr Beate Dielh
Institute of Neurology, University College London

PET-CT in Addiction
Dr Jeff W Dalley
Department of Psychology, University of Cambridge

Advances in brain PET and SPECT imaging: Emphasis on dementia
Prof Peter J Ell
Institute of Nuclear Medicine, London

Technical advances in brain imaging: Software
Dr John Dickson
Institute of Nuclear Medicine, London

LUNCH, Poster Session and Meet Industry in the Exhibition Hall

NUCLEAR MEDICINE IN EUROPE AND ASIA PACIFIC
Chairs: Dr Jamshed Bomanji
Mr Steve Ebdon-Jackson

Role of PET-CT in established and emerging clinical applications: The Danish experience
Dr Vineet Prakash
Ashford & St Peter’s NHS Trust
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Venue</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30</td>
<td>Role of Nuclear Medicine in image-guided surgery today and perspectives ahead</td>
<td>17.20</td>
<td>Role of PET-CT in Congenital Hyperinsulism</td>
</tr>
<tr>
<td>15.00</td>
<td>Affordable Nuclear Medicine: New tracers from India</td>
<td>17.40</td>
<td>PANEL DISCUSSION</td>
</tr>
<tr>
<td>15.30</td>
<td>Nuclear Medicine in the Middle East</td>
<td>18.00</td>
<td>COCKTAIL RECEPTION</td>
</tr>
<tr>
<td>16.00</td>
<td>PANEL DISCUSSION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.10</td>
<td>TEA and Meet Industry in the Exhibition Hall</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>ENDOCRINE AND EDUCATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td>Role of Radionuclide imaging in Thyroid and Parathyroid Surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>Use of “Ga-DOTATATE in paragangliomas</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MONDAY 22 SYNDICATE 1 & 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Venue</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td>1. Somatostatin Peptide Receptor Radionuclide Therapy (PRRT) with “Lu-DOTATATE for recurrent meningioma and pituitary adenoma (paper no. 5 in NMC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30</td>
<td>2. Is <strong>99m</strong>Tc-MIBI methoxyisobutylisonitril (&quot;mTc-MIBI&quot;) tissue elimination influenced by variation in the MDR1 gene?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45</td>
<td>3. Limiting Acute Nephrotoxicity in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Flow using “Rb-PET</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>4. Use of “Ga-DOTATATE in paragangliomas</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ENDOCRINE & MISCELLANEOUS**

- Chairs: Dr Richard Graham, Dr Francis Sundram

1. Somatostatin Peptide Receptor Radionuclide Therapy (PRRT) with “Lu-DOTATATE for recurrent meningioma and pituitary adenoma (paper no. 5 in NMC)
2. Is **99m**Tc-MIBI methoxyisobutylisonitril ("mTc-MIBI") tissue elimination influenced by variation in the MDR1 gene?
3. Limiting Acute Nephrotoxicity in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Flow using “Rb-PET
4. Use of “Ga-DOTATATE in paragangliomas

**ENDEO CRINE & MISCELLANEOUS**

- Chairs: Dr Richard Graham, Dr Francis Sundram

1. Somatostatin Peptide Receptor Radionuclide Therapy (PRRT) with “Lu-DOTATATE for recurrent meningioma and pituitary adenoma (paper no. 5 in NMC)
2. Is **99m**Tc-MIBI methoxyisobutylisonitril ("mTc-MIBI") tissue elimination influenced by variation in the MDR1 gene?
3. Limiting Acute Nephrotoxicity in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Flow using “Rb-PET
4. Use of “Ga-DOTATATE in paragangliomas

**ENDOCRINE & MISCELLANEOUS**

- Chairs: Dr Richard Graham, Dr Francis Sundram

1. Somatostatin Peptide Receptor Radionuclide Therapy (PRRT) with “Lu-DOTATATE for recurrent meningioma and pituitary adenoma (paper no. 5 in NMC)
2. Is **99m**Tc-MIBI methoxyisobutylisonitril ("mTc-MIBI") tissue elimination influenced by variation in the MDR1 gene?
3. Limiting Acute Nephrotoxicity in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Flow using “Rb-PET
4. Use of “Ga-DOTATATE in paragangliomas

**ENDOCRINE & MISCELLANEOUS**

- Chairs: Dr Richard Graham, Dr Francis Sundram

1. Somatostatin Peptide Receptor Radionuclide Therapy (PRRT) with “Lu-DOTATATE for recurrent meningioma and pituitary adenoma (paper no. 5 in NMC)
2. Is **99m**Tc-MIBI methoxyisobutylisonitril ("mTc-MIBI") tissue elimination influenced by variation in the MDR1 gene?
3. Limiting Acute Nephrotoxicity in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Flow using “Rb-PET
4. Use of “Ga-DOTATATE in paragangliomas

**ENDOCRINE & MISCELLANEOUS**

- Chairs: Dr Richard Graham, Dr Francis Sundram

1. Somatostatin Peptide Receptor Radionuclide Therapy (PRRT) with “Lu-DOTATATE for recurrent meningioma and pituitary adenoma (paper no. 5 in NMC)
2. Is **99m**Tc-MIBI methoxyisobutylisonitril ("mTc-MIBI") tissue elimination influenced by variation in the MDR1 gene?
3. Limiting Acute Nephrotoxicity in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT) Flow using “Rb-PET
4. Use of “Ga-DOTATATE in paragangliomas
11.30  8. Making the most of technology to improve throughput in bone scanning
I Armstrong, D Tout, G Al-Bahram, E Johnstone, J James
Central Manchester University Hospitals, UK

11.45  9. Incremental value of “F-Choline-PET-CT in detection and characterization of skeletal findings in suspected biochemical relapse: First UK experience
A Haroon, J Afgan, R Allie, R Endozo, M Emberton, J Bomanji
University College London Hospital, UK

12.00  10. Painful Knee Prosthesis: Can We Help with SPECT/CT?
K Al-Nabhan, J Alkalbani, S Michopoulou, R Syed, J Bomanji
Institute of Nuclear Medicine, University College London Hospital
NHS Trust, UK

12.15  11. Pelvic bone marrow involvement in metastatic prostate cancer – the role of isotope bone scan
M Jafari1, E Jefferson2, A Mackie3, I Minty4
1James Cook University Hospital, 2Regional Medical Physics Department, County Durham and Darlington NHS Foundation Trust, 3Radiology Department, County Durham and Darlington NHS Foundation Trust, UK

12.30  12. Validation of simultaneous 18F-Kr-99mTc dual isotope SPECT V/Q Acquisition
A Neale, A Notghi, K Alam, W Thornson
Sandwell and West Birmingham Hospital, UK

12.45  13. Planar images reprojected from SPECT V/Q data perform similarly to traditional planar V/Q scans in the diagnosis of pulmonary embolism
P Kyratos, S Navalkissoor, M Burniston, F Wickham, T Wagner
Nuclear Medicine Department, Royal Free London NHS FT, UK

13.00  14. Design, execution and testing of a phantom to allow optimisation of simultaneous dual isotope Krypton SPECT V/Q imaging
CD Baker, JCM Fowler
Royal Brompton and Harefield NHS Foundation Trust, East and North Hertfordshire NHS Trust, UK

13.15  15. Implementing a system for receiving O gas in a PET scanner room
N Bird, G Whish, S Yates
Addenbrooke’s Hospital, Cambridge, UK

13.30  16. Predicting the optimal number of Eigenimages to be used in a diagnostic normal brain atlas
C H Bjuren, S D Bloomer, A S Houston
1University of Stirling, 2Hermes Medical Solutions, London, UK

13.45  17. Is Monte Carlo Scatter Correction (MCSC) of 18F without collimator response modelling sufficient for studies acquired with LEHR collimators?
CM Brown1, G Gillen1, J Prosser1, MF Dempsey2
1Gartnavel General Hospital, Glasgow, UK

F Ortega-Nava, J Jiménez-Bonilla, I. Banzo, I. Martínez-Rodríguez, E. Rodríguez, I. Mateo, R. Del Castillo-Matos, N. Martínez-Amador, J.M Carril
Marqués de Valdecilla University Hospital, University of Cantabria, Santander, Spain

14.15  19. An assessment of the role of FDG PET in the decision making for Epilepsy Surgery
JC Dickson1, C Rathore2, PJ Elliot, JS Duncan
1Institute of Nuclear Medicine, University College London Hospital, 2Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, London, UK

14.30  20. Evaluation of the clinical effectiveness of FDG-PET-CT in the diagnosis of early dementia
E Cunningham, P Fearon, P Passmore, D Craig, S Todd, S Hughes
Belfast HSC Trust, UK

14.45  21. Quantitative assessment of the reproducibility of specific binding ratio in full and reduced activity pre-synaptic dopamine transporter imaging with [123I]-FP-CIT
SA Smith1, J Prosser1, J Robinson1, CA Paterson1, G Dewar1, W Martin1
1Nuclear Cardiology, Glasgow Royal Infirmary, 2Nuclear Medicine, Gartnavel General Hospital, Glasgow, 3Nuclear Medicine, Royal Hospital, Larbert, UK
Programme

MONDAY 22 SYNDICATE 3 & 4

16.30  22. Effect of transverse tilt on quantification in [123I]-FP-CIT SPECT
        M Burniston, P Kyrtatos, T Wagner, F Wickham
        Royal Free NHS Foundation Trust, London, UK

16.45  23. What is the impact of MR based attenuation correction on standard and quantitative neurological PET/MR?
        JC Dickson, A Barnes, C O’Meara, LJ Menezes
        Institute of Nuclear Medicine, University College London Hospital, UK

18.00  COCKTAIL RECEPTION
        The Restaurant, 3rd Floor

17.00  Business Plan for a PET-CT Service
        Dr Simon Hughes
        Nottingham City Hospital

17.30  Changing Landscape in Paediatric Imaging
        Dr Tom Lynch, Belfast City Hospital

17.45  Planning for SPECT/CT before and after installation
        Danny McCool
        Royal Free Hospital

18.00  COCKTAIL RECEPTION
        The Restaurant, 3rd Floor
**TUESDAY 23 AUDITORIUM 2**

**CARDIOLOGY I**
Chairs: Dr Parthiban Arumugam, Prof Richard Underwood

09.00 Impact of NICE Guidelines on MPS Imaging
Prof Richard Underwood
Imperial College London (National Heart and Lung Institute)

09.30 MPS Morphing with Competing Modalities
Dr Nikant Sabharwal
Oxford Heart Centre. John Radcliffe Hospital

10.00 Emerging Applications: Focus on Sarcoidosis and Amyloidosis
Dr Leon Menezes
Institute of Nuclear Medicine, UCLH

10.30 Technical Advances: New cameras and software for Myocardial Perfusion and Function
Prof Brian Hutton
Institute of Nuclear Medicine UCLH

09.50 11.00

11.15 Do’s and Don’ts to maintain high quality imaging: Clinical Practitioners’ View
Carl Grimsditch
Central Manchester University Hospitals NHS Foundation Trust

09.50 11.00

11.15 Do’s and Don’ts to maintain high quality imaging: Clinical Practitioners’ View
Carl Grimsditch
Central Manchester University Hospitals NHS Foundation Trust

10.50 PANEL DISCUSSION

11.00 COFFEE and Meet Industry in the Exhibition Hall

**ONCOLOGY I**
Chairs: Dr Wai-Lup Wong
Dr Alexis Corrigan

11.00 Impact of NICE Guidelines on MPS Imaging
Prof Richard Underwood
Imperial College London (National Heart and Lung Institute)

11.30 PET-CT: Where are we in current guidelines in cancer imaging
Dr Sally Barrington
Guy’s & St Thomas’ NHS Trust

11.50 PET-CT in Gynaecological Malignancy
Dr Tara Barwick
Charing Cross Hospital

12.00 PET-CT/MRI in Prostate Cancer
Dr Athar Haroon
Institute of Nuclear Medicine, UCLH

12.15 PET-CT in Paraneoplastic Syndrome
Dr Sai Han
Glasgow Royal Infirmary

12.30 PANEL DISCUSSION
LUNCH and Meet Industry in the Exhibition Hall

13.00 Medics Forum

13.15 SpR Forum, Meeting Room 1

14.00 ANNUAL LECTURE
Chairs: Dr Brian Neilly, Prof Alan Perkins

**Advances in High Resolution Multi-Modality Imaging: from Physicist to Physician**
Professor David Townsend
PET and SPECT Development Group, Singapore Bioimaging Consortium

TEA, POSTER VIEWING and Meet Industry

15.00

15.30 UK PET Physics Group Radiation Protection in PET – in principle and in practice

BNMS ANNUAL GENERAL MEETING

**TUESDAY 23 SYNDICATE 1 & 2**

**CLINICAL PRACTITIONERS**
Chairs: Sandra Johns, Lloyd Rowling

09.00 24. Brain imaging (SPECT) vascular perfusion deficits and survival in late onset dementia: a longitudinal observational study
L Lambley¹, A Murray², L Whalley², L Lovell¹, R Staff
¹Aberdeen Royal Infirmary, ²Aberdeen University, UK

09.15 25. The added benefit of quantitative MBF to standard 82Rb PET MPI and the correspondence to anatomical changes
M Meintjes, R Endozo, J Dickson, L Menezes, J Bomanni
University College London Hospital, UK

09.30 26. Gastric Emptying Studies, an audit of methodology
A French
Glasgow Royal Infirmary, UK

09.45 27. An introduction to Magnetic Resonance (MR) artefacts for Nuclear Medicine technologists – A brief introduction to their causes and how to resolve them
C O’Meara, S Burns, A Barnes, R Syed, L Menezes, J Bomanni
University College London Hospital, UK
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10.00 | 28. Operator variability in the analysis of multi gated acquisition (MUGA) data to assess left ventricular ejection fraction  
A Nunes, M Luqman, Y Bouchareb, H Jan, E Joel, N Macalintal, A Nacpil, V Paldo, N Swadling, L Tri-Ajil  
Barts Health NHS Trust, London, UK |
| 10.15 | 29. Do DMSA defects evident between 3 and 6 months post UTI represent scarring?  
D Wright, E Jefferson, A Mackie  
University Hospital of North Durham, UK |
| 10.30 | 30. Evaluating role of $^{99m}$Tc Pertechnetate and Dynamic $^{99m}$Tc MIBI imaging coupled with SPECT/CT scan for localisation of Parathyroid adenoma  
A Nunes, A Haroon, M Luqman, L Childs, A Hameeduddin, I Goddard, L Biassoni, T Szyszko, H Jan  
Barts Health NHS Trust, London, UK |
| 10.45 | COFFEE and Meet Industry in the Exhibition Hall |
| 11.00 | 31. A comparison between supine and seated myocardial perfusion imaging with attenuation correction  
D Tout, C Tonge, J Adams, P Austin, K Colligan, P Arumugam  
Central Manchester University Hospitals NHS Foundation Trust, UK |
| 11.15 | 32. Characterization Of The Mineral Deposition And The Inflammatory Metabolism Of The Carotid Atheroma By $^{18}$F-Fluoride And $^{18}$F-FDG PET-CT  
Marqués de Valdecilla University Hospital, University of Cantabria, Santander, Spain |
| 11.30 | 33. Are One Compartment and Retention models comparable for the quantification of Myocardial Blood Flow using “Rb”?  
JC Dickson, M Meintjes, LJ Menezes, AM Groves  
Institute of Nuclear Medicine, University College London Hospital, UK |
| 11.45 | 34. A Quantitative Comparison of Planar vs. SPECT MUGA  
‘City Hospital, Birmingham, ‘University Hospitals Coventry and Warwickshire, UK |
| 12.00 | 35. LVEF Determination using IQ-SPECT and conventional SPECT: comparison with Cardiac MRI  
N Bebbington, C Boivin, E Lanchbury, M Wilson, R Steeds  
The Queen Elizabeth Hospital Birmingham, UK |
| 12.15 | 36. Association of Transient ischemic dilation (TID) ratio with severity and extent of Coronary artery disease (CAD) as assessed by Dipyridamole $^{99m}$Tc x 2 Tracer Myocardial Perfusion SPECT (MPS): Comparison with Exercise $^{99m}$Tc x 2 Tracers MPS  
‘Nuclear Institute of Medicine and Radiotherapy (NIMRA), Jamshoro, Pakistan, ‘Fujairah Hospital, Fujairah, United Arab Emirates, ‘Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi, Pakistan |
| 12.30 | 37. Advanced reconstruction does not change coronary flow reserve estimation in dynamic “Rb cardiac PET  
IS Armstrong, CM Tonge, P Arumugam  
Central Manchester University Hospitals, UK |
| 13.00 | LUNCH and Meet Industry |
| 13.15 | BNMS Clinical Practitioners’ AGM  
ONCOLOGY II  
Chairs: Dr Thomas Wagner  
Dr Rakesh Kumar, Dr Zarni Win |
| 13.45 | 38. Impact of “$^{18}$FDG PET-CT in suspected or confirmed early stage non-small cell lung cancer  
D Colville’, S Han’, FW Poon’, JB Neilly’  
‘Beatson West of Scotland Cancer Centre, Glasgow, ‘Glasgow Royal Infirmary, UK |
| 14.00 | 39. Response and Survival in Oesophageal Cancer Patients Following Neoadjuvant Chemotherapy Assessed by FDG-PET-CT and Correlation to Pathological Response  
S Hughes, Y Manikyam, C Harrison, D McManus, C Boyd, PA Carey, JA Kennedy, K McManus, M Eatock  
Belfast HSC Trust, UK |
41. Uptake of $^{15}$C Choline, $^{18}$F Methyl Choline and $^{18}$F Ethyl Choline: Physiological distribution, statistical differences and imaging pearls
*University College London Hospital NHS Trust, 'University Hospital Sant'Orsola Malpighi, Bologna, Italy, †Masjed University of Medical Sciences Iran, ‘St. Vincent’s Hospital, Austria

43. Contrasting relations with blood glucose level of FDG accumulation in the brain and liver: potential clinical impact

44. Value Of Baseline $^{18}$F-FDG PET Quantitative Imaging Parameters For Predicting Treatment Response in Hodgkin’s Lymphoma
B Taylor*, M Siddiquie*, S Barrington*, NG Mikhaeel†, G Cook* 
‘King’s College London, ‘Guy’s & St Thomas’ NHS Foundation Trust, UK

45. Simultaneous PET/MRI vs PET-CT in Oncological Patients: measured exuberance
Institute of Nuclear Medicine, London, UK

RADIOPHARMACY I
Chairs: Paul Maltby, Bev Ellis
Update on new Non-PET Tracers coming to Market
Dr Jim Ballinger
Guy’s & St Thomas’ NHS Foundation Trust
Update on New PET Tracers coming to Market
Prof Eric Aboagye 
Department of Surgery and Cancer, Imperial College
Resurrecting the power of Radiochemistry for Molecular Imaging
Dr Erik Arstad
University College London
The Role of IAEA in fostering use of Radiopharmaceuticals
Mr Uday Bonsale 
International Atomic Energy Agency, Austria

COFFEE and Meet Industry in the Exhibition Hall

RADIOPHARMACY II
Chairs: Jilly Croasdale, Bev Ellis
46. Routine preparation of $^{18}$Y, $^{18}$Lu, and $^{111}$In-DOTATATE for treatment of neuroendocrine tumours
J Ballinger, Y Tan, S Allen, Y Lewington 
Guy’s and St Thomas’ NHS Foundation Trust, London, UK

LUNCH and Meet Industry
16.30
52. Axillary surgery has no acute effect on lymphatic function in patients with breast cancer
S Bains, S Allen, J Ballinger, Y Tan, L Jenkins, A Stanton, J Levick, A Purushothaman, A Peters, P Mortimer
‘King’s College London, ‘Guy’s and St Thomas’ NHS Foundation Trust, ‘St George’s, University of London, ‘Brighton and Sussex University Hospitals NHS Trust, UK

16.50
PET Travelling Fellowship 2012 - Experience of PET-CT imaging at the UniversitatsSpital, Zurich
Dr Alexis Corrigan
Royal United Hospital Bath

17.15
GENERAL NUCLEAR MEDICINE II
Chairs: Dr Alp Notghi
Dr Jackie James

08.30
Changing Landscape for Nuclear Medicine Trainees: Prepare yourself
Dr Liz Pruvolovich
Institute of Nuclear Medicine, London

08.50
The next generation of Medics: Guidance from the BNMS President
Dr Brian Neilly
Glasgow Royal Infirmary

09.10
Sentinel node imaging: Current status and future directions
Dr Rosemary Allan
St George’s Healthcare NHS Trust

09.30
Liver transplant imaging
Dr Nicola Mulholland
King’s College Hospital, London

09.50
PANEL DISCUSSION

10.00
COFFEE and Meet Industry in the Exhibition Hall

ONCOLOGY II
Chairs: Prof Adil Al-Nahhas
Prof Alan Perkins

10.30
Current Practice and Controversies in Radionuclide Therapy for NETS
Prof Martyn Caplin
Royal Free Hospital, London

10.50
Selection and follow up of patients with NETS
Dr Shaunak Navalkissoor
Royal Free Hospital, London

11.10
Current Practice and Controversies in Radionuclide Therapy for DTC
Dr Ujjal Malick
Northern Centre for Cancer Care Freeman Hospital, Newcastle

11.30
Management strategy in Iodine-Negative/Thyroglobulin-Positive Patients
Prof Sobhan Vinjamuri
Royal Liverpool Hospital

11.50
Do’s and Don’ts to maintain a high quality Therapy Unit – Physicist’s View
Richard Fernandez
Guy’s & St Thomas’ Hospital NHS Foundation Trust

12.15
PRIZE PRESENTATION

12.30
HIGHLIGHTS LECTURE
Prof John Buscombe
Addenbrooke’s Hospital, Cambridge

13.15
COMPLIMENTARY LUNCH and CLOSE OF MEETING
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.45</td>
<td>57. The role of contrast enhanced computer tomography in PET-CT in localisation of liver metastases from primary colorectal cancer</td>
<td>S.J Ong, A.C Gomez, S Whitley, J.R Buscombe Addenbrooke’s Hospital, Cambridge, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>UK</td>
</tr>
<tr>
<td>10.00</td>
<td>COFFEE and Meet Industry in the Exhibition Hall</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 10.30 | 58. Liver directed treatment with SIRT in unresectable colorectal carcinoma liver metastasis: 4 year experience from the Central South Coast of England | S Leach, M Kay, B Stedman, F Sundram  
Department of Nuclear Medicine,  
Department of Interventional Radiology, University Hospital Southampton, UK |
| 11.00 | 59. Early clinical experience of dynamic "F Fluoroethyl Choline PET-CT(FCH) in differentiating tumoural/radiation necrosis from viable brain tumour, compared to combined MRI/DWI. Is combined T/B and time activity curve(TAC) pattern analysis a reliable discriminating tool? | S Chua, HY Loi, J Gear, I Zerizer, D Levine, Y Du, I Chau, I Murray, F Saran  
The Royal Marsden NHS Foundation Trust, London, UK |
| 11.15 | 60. Assessment of tumour heterogeneity before and after CA1P anti-vascular therapy in two different metastatic colorectal models on "18F i-A5B7 (anti-CEA) SPECT imaging | GJR Cook, V Rajkumar, V Goh, M Siddique, M Robson, G Boxer, B Pedley  
KCL, London, UK  
Royal Marsden Hospital, Sutton, London, UK  
Institute of Cancer Research, Sutton, London, UK |
| 11.15 | 61. Patient-specific tumour dosimetry for 82Rb-HEDP therapy of bone metastases from prostate cancer | A M Denis Bacelar, A Divoli, S Chittenden, Y Du, D P Dearnaley, J M O’Sullivan, G D Flux  
Institute of Cancer Research, Sutton, London, UK  
Royal Marsden Hospital, Sutton, London, UK  
Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK |
Programme

WEDNESDAY 24 SYNDICATE 3 & 4

08.30 Nuclear Medicine Therapy Group (Molecular Radiotherapy)
Molecular radiotherapy in the UK: Toward evidence-based harmonisation

SPECIAL INTEREST GROUP
Chairs: Dr Glenn Flux, Prof Sobhan Vinjamuri

10.00 COFFEE and Meet Industry in the Exhibition Hall

PHYSICS II
Chairs: Sarah Allen, Dr Alison Bolster

10.30 62. Eye Dose measurements in a wide range of Nuclear Medicine departments indicate that it is unlikely that staff will need to be classified
J Prince, B Murby
The Christie NHS Foundation Trust, Manchester, UK

10.45 63. Evaluation of the cyclotron-produced praseodymium oxide radioactivity: Enhancement of the therapeutic properties of 142PrO₃ as a multifunctional agent
MK Bakht, M Bakhtiar, M Hussain, M Sadeghi, SJ Ahmadi, C Tenreiro
'Young Researchers and Elites Club, Science and Research Branch, Islamic Azad University, Tehran, Iran,
'Department of Physics, Persian Gulf University, Bushehr, Iran,
'Department of Physics, Government College University Lahore, Pakistan,
'Agricultural, Medical and Industrial Research School, Nuclear Science and Technology Research Institute, Karaj, Iran,
'Jaber Ibne Hayyan Research Laboratories, Nuclear Science and Technology Research Institute, Tehran, Iran,
'Department of Energy Science, Sungkyunkwan University, Suwon, Republic of Korea

11.00 64. A New Concept for "SeSeH CAT studies with a Gamma Camera
WH Thomson, J O'Brien, G James, M Williams, A Notghi
'City Hospital, Birmingham,
'Velindre Hospital, Cardiff, UK

12.15 PRIZE PRESENTATION
(Auditorium 2)

12.30 HIGHLIGHTS LECTURE
(Auditorium 2)

13.15 COMPLIMENTARY LUNCH and CLOSE OF MEETING
P1. Radial quantitative ultrasound in comparison to dual-energy x-ray absorption tomography in the osteoporosis clinic: An institutional experience combined with meta-analysis of published literature
J Shur, H Hardiman, H Alexander, AM Peters, S Dizdarevic Bright and Sussex University Hospitals NHS Trust, UK

P2. Appropriate Referrals for Myocardial Perfusion Scans
S Thompson, E Winston, N Bhonsele, M Noor, E Einaas Barking, Havering, & Redbridge University Trust, Essex, UK

P3. Perfusion only technetium scans can be used in the management of young patients with suspected pulmonary embolus
D Newman, N Gurjar, L Fowkes, A Karuppih, C Beadsmoor ‘Norfolk & Norwich University Hospital, ‘Nottingham City Hospital, UK

P4. A Case Series Review of Interesting Incidental Extra-Cardiac Findings in Myocardial Perfusion Scintigraphy
K Alam, A Notghi, J O’Brien, M Pandit SWBH NHS Trust, Birmingham, UK

P5. Investigation into the Performance of Resolution Recovery in Analysing Gated MPI Studies
A Jennings, J O’Brien, G James, WH Thomson City Hospital, Birmingham, UK

P6. Myocardial Perfusion Studies (MPS) with arms down – could a 360 degree orbit help?
J O’Brien, WH Thomson, GD James, MM Pandit, A Notghi Sandwell & West Birmingham Hospitals NHS Trust, UK

P7. Incremental value of Lymphoscintigraphy SPECT/MR in lymphangiomatous chylodermatium
G Rijju, G Aruri, J Vithin, G Nissy, D Dincy ‘MIMS, Calicut,Kerala, ‘MCH, Calicut,Kerala, India

P8. Lipomatous hypertrophy of the interatrial septum; imaging features on PET-CT
C. Kelly-Morland, D. Newman, CJ Beadsmoor Norfolk and Norwich University Hospitals NHS Foundation Trust, UK

P9. “125m-Tc-Nanocolloid SPECT/CT and a Portable Gamma Camera for Image-Guided Sentinel Node Biopsy in head and neck malignancy: Science & Practice
J Connelly, G Granasegaran, C Schilling, M McGurk Department of Nuclear Medicine and Maxillofacial Surgery Guys & St Thomas’ Hospital NHS Trust, London, UK

S Eljamel, Z Khan Western General Hospital, Edinburgh, UK

P11. Outcome of Iodine ¹³¹Therapy for Hyperthyroidism in Hospital Kuala Lumpur, Malaysia
Z Awang Universiti Sains Malaysia, Pulau Pinang, Malaysia

P12. Value of delayed ¹²³Iodine-norcholesterol imaging in primary aldosteronism (Conn’s syndrome): Old test revisited
A Hosur, N Singh, A.M Peters, E Sellon, S Dizdarevic Brighton and Sussex University Hospital NHS Trust, UK

P13. The value of pertechnetate thyroid imaging prior to radioactive iodine-131I treatment – our experience
K Alam, A Notghi City Hospital, Birmingham, UK

P14. CASE REPORT: Lingual thyroid: the role of radioiodine in diagnosis and therapy
M Neilly, D Colville, O Hilmi, G McGarry, B Neilly ‘Department of Nuclear Medicine, Glasgow Royal Infirmary, ‘University of Dundee Medical School, Dundee, ‘ENT Department, Glasgow Royal Infirmary, UK

P15. Error Analysis of SeHCAT Retention for Collimated Gamma Cameras
G James, WH Thomson, J O’Brien King’s College London School of Medicine, City Hospital, Birmingham, UK

P16. Is ¹³¹I in WCC SPECT/CT of value in patients with clinically suspected infection?
F Dambha, E Nowosinska, J Buscombe Addenbrookes Hospital, Cambridge, UK

P17. CASE REPORT: Disseminated osteomyelitis or bone metastases of breast cancer: FDG PET-CT helps targeting lesion for biopsy
R Mandegaran, A Debard, M Alvarez, B Marchou, P Massip, T Wagner ‘The Royal Free Hospital, London, UK ‘Toulouse University Hospital, Toulouse, France

P18. Increased operational flexibility through the use of perfusion-only studies in pregnant patients with suspected pulmonary embolus
A Gemmell, A Nicoli, B Mucci Southern General Hospital, NHS Greater Glasgow & Clyde, UK

P19. A Pictorial Review of SPECT Ventilation-Perfusion (VQ) Images – Interesting Cases
CS Low, K Alam, A Notghi, J O’Brien Physics and Nuclear Medicine Department, City Hospital, Birmingham, UK

P20. Use of a Delay Volume Insert for Optimisation of SPECT V/Q with ¹³¹I Kr
WH Thomson, A Neale, J O’Brien City Hospital, Birmingham, UK
P21 SPECT V/Q with 81mKr. Effect of Gas Leakage on Image Quality and Optimisation of the Imaging Process
WH Thomson, J O’Brien, G James, M Pandit, A Notghi City Hospital, Birmingham, UK

P22 Variability of krypton delivery rate to patients undergoing SPECT V/Q scans and its impact on clinical images
M Burniston, T Wagner, R Leshen, J Page Royal Free NHS Foundation Trust, London, UK

P23 Patients of Multicultural Society Attending Nuclear Medicine Department: Breaking the Communication Barrier
R Sajjan1, K Al-Nabhani, Z Saad, E Panagiotidis, S Salam1, R Syed, J Bomanj1
1Institute of Nuclear Medicine, UCLH, London,
2Department of Nuclear Medicine, Kings College, London, UK

P24 A Study of Delayed Cardiotoxicity in Trastuzumab treatment using multi gated acquisition scans (MuGA)
E Gill, J Buscombe
1University of Cambridge, 
2Addenbrooke’s Hospital, Cambridge, UK

P25 The significance of uptake in the thyroglossal tract on ¹³¹I-SPECT/CTscan in thyroid cancer patients post ablation and its correlation with TSH and tumour markers
F Dambha, E Nowosinska, J Buscombe
Addenbrookes Hospital, Cambridge, UK

P26 Audit of parameters affecting diagnostic quality of FDG-PET scans
L Millar, E Kalkman
PET-CT Centre, The Beatson West of Scotland Cancer Centre, Glasgow, UK

P27 The use of FDG PET-CT in patients with early operable breast cancer
R Duguid1, A Denison, SD Heys, L Lovell, F McKiddie1, L Melville, S Olson, E Ramage, S Starface, RT Staff
1NHS Grampian, Aberdeen, 
2University of Aberdeen, UK

P28 SPECT/CT Sentinel Lymph Node Biopsy: Adding more to hotspots
C Sit, J Connelly, M Hosahalli, G Gnanasegaran
Guys & St Thomas’ Hospital NHS Trust, London, UK

P29 Pictorial review of PET-CT & SPECT/CT in functional imaging of Prostate Cancer: All You Need to Know
C Sit1, S Lewitschnig1, J Connelly1, S Osmany1, G Gnanasegaran1
1Guys & St Thomas’ NHS Trust, London, UK
1Radlink PET & Cardiac Imaging Centre, Singapore

P30 Sentinel Node Biopsy for Head and Neck Melanoma: development of a service and initial results
T Aldridge, F Sundram, S John, G Davies, V Battery, S Sharma
Dept. of Oral & Maxillofacial Surgery, University Hospitals Southampton NHS Foundation Trust, UK

P31 “SNL: Torbay’s Experience”
A Vaz
EHKFT, Canterbury, UK

P32 Molecular imaging of Dermatomyositis-Polymyositis complex: Use of Magnetic Resonance Imaging, Bone Scan and “F-FDG PET-CT as an investigational tool
S Bhatia, A Haroon, F Karim, K Centa, K L Tan, C Padmanathan, H Jan
Barts Health NHS Trust, London, UK

P33 Counteracting brown fat: an audit on the introduction of beta blockade in paediatric FDG PET-CT
D Neerim, R Allie, L Menezes
Institute of Nuclear Medicine, University College London Hospital, UK

P34 Children are not little adults: Our experience of setting up a new paediatric isotope imaging service within an existing District General Hospital nuclear medicine department
S Amonkar, L Tandon, R Fernando
Pennine Acute Hospitals NHS trust, Manchester, UK

P35 Absent bilateral basal-ganglia uptake on ¹⁸F-fluorodeoxyglucose (FDG) PET-CT: A case report with literature review and comparison to ¹²³I-DaTSCAN findings
J Shur, N Kock, G Burkill, S Dizdarevic
Brighton and Sussex University Hospitals NHS Trust, UK
P36  Early detection of recurrence of colorectal carcinoma on \textit{\textsuperscript{18}F-FDG} PET-CT and its correlation with other clinicopathological parameters
\textit{Shaukat Khanum Memorial Cancer Hospital & Research Center, Nuclear Medicine},
\textit{Shaukat Khanum Memorial Cancer Hospital & Research Center, Radiology},
\textit{Shaukat Khanum Memorial Cancer Hospital & Research Center, Medical Oncology},
\textit{Shaukat Khanum Memorial Cancer Hospital & Research Center, Surgical Oncology},
\textit{Shaukat Khanum Memorial Cancer Hospital & Research Center, Pathology}, Lahore, Pakistan.

P37  How Sharp is “SharpIR”?
N Vennart, I Cullum, N Bird.
\textit{Cambridge University Foundation Hospitals Trust, UK}.

P38  Patient hyperhydration and delayed urinary bladder studies improve \textit{\textsuperscript{18}F-Flurorodeoxyglucose (\textit{\textsuperscript{18}F-FDG}) PET-CT detection of bladder wall neoplasms}
E. Perrone, F. Barbano, E. Caló, A. Cistermimno, G. Valle.
\textit{PET Unit of the Scientific Institute Casa Sollievo della Sofferenza},
\textit{Urology Unit of the Scientific Institute Casa Sollievo della Sofferenza},
\textit{Nuclear Medicine Unit of the Scientific Institute Casa Sollievo della Sofferenza, Italy}.

P39  Medical Imaging Utilising Zirconium Complexes
T Ferris, P Charoenphun, M Went, P Blower.
\textit{The University of Kent at Canterbury, ‘King’s College London, UK}.

P40  CASE REPORT: Increased FDG uptake in PET imaging of intraocular prosthesis in a patient with previous choroidal melanoma
S Haldar, S Dizdarevic, G Burkill, J Hungerford, V Raman.
\textit{Brighton & Sussex University Hospitals, ‘Moorfields Eye Hospital, London, UK}.

P41  Imaging Hypoxia- The Synthesis of Asymmetric Copper (II) Bis(thiosemicarbazones)
O Brown, J Bagunya Torres, M Went, P Blower.
\textit{University of Kent, Canterbury, ‘Kings College, London, UK}.

P42  Value of \textit{\textsuperscript{18}F FDG-PET-CT brain imaging in the syndromic characterization of primary progressive speech disorders}
J Shur, KK Moody, D Chan, G Keramida, G Burkill, S Dizdarevic.
\textit{Brighton and Sussex University Hospitals NHS Trust, ‘Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, University of Sussex, UK}.

P43  Whole Body PET-CT vs Conventional CT in the Staging of Lung Cancer
L A Fowkes, C J Beadsmoore, M Crawford.
\textit{Norfolk & Norwich University Hospital, UK}.

P44  Comparison of FDG PET-CT characteristics of adenocarcinoma and squamous cell carcinoma of the oesophagus
T Westwood, T Ransome, J Hill.
\textit{Royal Preston Hospital, UK}.

P45  Correlation between Textural Features of \textit{\textsuperscript{18}F-FDG PET in oesophageal cancer}
M Siddique, V Goh, P Marsden, B Taylor, M Blake, G Cook.
\textit{King’s College London, UK}.

P46  Investigation into effects of Time of Flight, Resolution Recovery and Reconstruction Iterations on reconstructed PET images acquired using a GE Discovery 690 PET-CT System
C McKeown, MF Dempsey, G Gillen, J Prosser, C Brown.
\textit{NHS Greater Glasgow and Clyde, UK}.

P47  Cardiac \textit{\textsuperscript{82}Rb PET: Development of Practice}
D Tout, I Armstrong, C Tonge, P Arumugam.
\textit{Central Manchester University Hospitals NHS Foundation Trust, UK}.

P48  FLT PET breast cancer exhibits 3D fractal characteristics pre and during therapy
\textit{Paul Strickland Scanner Centre, Mount Vernon Hospital, ‘Mount Vernon Hospital, UK}.

P49  PET-CT in Interstitial Lung Disease
\textit{University College Hospital, London, ‘Royal Brompton Hospital, ‘Lister Hospital, Stevenage, ‘GlxaoSmithKline, Stevenage, UK}.

P50  Review - Can treatment response be predicted using FLT PET-CT?
\textit{Paul Strickland Scanner Centre, Mount Vernon Hospital, ‘Mount Vernon Hospital, UK}.

P51  FLT PET-CT breast cancer distinguished with 3D lacunarity analysis pre and post therapy
\textit{Paul Strickland Scanner Centre, Mount Vernon Hospital, ‘Mount Vernon Hospital, UK}.
P52 Impact of matching SUV recovery or background noise on signal to noise with advanced PET reconstructions
IS Armstrong\(^1\), MD Kelly\(^1\), HA Williams\(^1\), JC Matthews\(^1\)
\(^1\)Central Manchester University Hospitals, 
\(^2\)University of Manchester, UK

P53 Can an ECG simulator be used to generate reduced count SPECT data?
CM Brown\(^1\), G Gillen\(^2\), J Prosser\(^2\), MF Dempsey\(^3\)
\(^1\)University of Glasgow, 
\(^2\)Gartnavel General Hospital, Glasgow, UK

P54 Is SPECT contrast recovery of the PET NEMA IEC Body phantom dependent on sphere positioning?
CM Brown\(^1\), G Gillen\(^2\), J Prosser\(^2\), MF Dempsey\(^3\)
\(^1\)University of Glasgow, 
\(^2\)Gartnavel General Hospital, Glasgow, UK

P55 Reduced Dose/Time \(^99m\)Tc MIBI Myocardial Perfusion SPECT (MPS) with Resolution Recovery (GE: Evolution for Cardiac) versus Full Time MPS with FBP and RR: Is reduced count data diagnostically acceptable?
S Michopoulos, J.C Dickson, E Panagiotidis, R Sajjan, W.A Waddington
Institute of Nuclear Medicine, University College London Hospital, UK

P56 Quantitative Image Reconstruction using Anatomical Information during Reconstruction
S Cronin\(^1\), M Partridge\(^2\), A Denis Bacelar\(^3\), G Flux\(^4\)
\(^1\)The Institute of Cancer Research & Royal Marsden Hospital, London, 
\(^2\)Gray Institute for Radiation Oncology & Biology, Oxford, UK

P57 Pixion® Planar Processing Improves Lesion Detection for \(^99m\)Tc-MIBG Studies
N Bebbington, L Jenkins, M Wilson, E Lanchbury, S Holt
The Queen Elizabeth Hospital Birmingham, UK

P58 Radionuclide Calibrator Linearity Tests – Taking Greater Care to Save Time?
S Dainty, C Williams, R Morton
University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, UK

P59 An Audit of Image Uniformity in SPECT Imaging
M Avison
Bradford Teaching Hospitals NHS Foundation Trust, UK

P60 CT Numbers in SPECT/CT: an unstable calibration or just chasing errors?
A Smout\(^1\), J Hall\(^2\), A Fullbrook\(^3\), J Ward\(^2\), L Wright\(^2\)
\(^1\)Royal Surrey County Hospital, Guildford, 
\(^2\)Frimley Park Hospital, Surrey, UK

P61 Comparison of Nuclear Medicine staff finger doses in a Department with PET-CT facilities to those observed from the Pan European ORAMED\(^1\) study
J Cullis, N Williams, C Koller
University Hospital Coventry, UK

P62 Radiation Dose Considerations for Patients and Staff for \(^99m\)Kr V/Q SPECT
WH Thomson
City Hospital, Birmingham, UK

P63 Radiosynovectomy in patients with Haemophilia: Science & Practice
J Connelly, A Desai, S Austin, D Back, S Vijayanathan, G Gnanasegaran
Departments of Nuclear Medicine, Radiology, Haemophilia & Orthopaedics Guy’s & St Thomas Hospital NHS Foundation Trust, London, UK

P66 Metrology for \(^90\)Y Microspheres
A Fenwick, M Baker, K Ferreira, L Johansson
National Physical Laboratory, Middlesex, UK

P67 qDose, a treatment planning tool for individualised, dosimetry based radionuclide therapy
KJ Frisch\(^1\), AM DenisBacelar\(^2\), J Gear\(^4\), G Flux\(^4\)
ICR, London, Royal Marsden Hospital, London, UK

P56 Quantitative Image Reconstruction using Anatomical Information during Reconstruction
S Cronin\(^1\), M Partridge\(^2\), A Denis Bacelar\(^3\), G Flux\(^4\)
\(^1\)The Institute of Cancer Research & Royal Marsden Hospital, London, 
\(^2\)Gray Institute for Radiation Oncology & Biology, Oxford, UK

P64 Liver directed treatment with selective internal radiation therapy (SIRT): 4 year experience
M Kay, S Leach, B Stedman, F Sundram
University Hospital Southampton NHS Trust, UK

P69 Practical patient-specific bone marrow and organ dosimetry for Yttrium-90 radio-labelled anti-CD66 MAB molecular radiotherapy
MJ Guy, J Langford, G Lewis, KH Orchard
University Hospital Southampton, UK
Molecular radiotherapy: how much dose is the patient really getting?
V Smyth*, C Bobin†, L Johansson*, M d’Arienzo*, M Cox, J_olec
National Physical Laboratory, Teddington, UK
*Laboratoire National Henri Becquerel of the Commission for Atomic Energy, Saclay, France
†The National Institute of Itonising Radiation Metrology, Rome, Italy
‡Cesky Metrologicky Institut Brno, Brno, Czech Republic

Molecular radiotherapy: how much dose is the patient really getting?

Radiopharmaceutical and Nuclear Medicine Imaging Characteristics of 99mTc Water Soluble Chitosan Derivatives
H Farag*, R Hassanb, DI El-Hawary*, M Motaleb,
*Department of Nuclear Engineering, Faculty of Engineering, Jeddah, Saudi Arabia,
†Department of Nuclear Medicine, National Cancer Institute, Cairo, Egypt,
‡Department of Chemistry, Faculty of Science, Cairo University, Egypt,
Department of Labeled Compounds, Hot Labs Center, Atomic Energy Authority, Cairo, Egypt

Comparison of two methods for labelling white cells with 111In-oiline
E Papadopoulos, GA Wright, G Avery
Hull and East Yorkshire Hospitals NHS Trust, UK

MAG3 renography revisited
P. S Cosgriff, M Aslam
United Lincolnshire Hospitals, Boston, UK

Accuracy of single sample techniques for assessment of Glomerular Filtration Rate (GFR) and their dependence on sampling time, renal function and extracellular fluid volume (ECFV)
F Wickham, H McMeekin, M Burniston
Royal Free London NHS Trust, UK

The importance of patient positioning with IGSPECT™
A. Paramithas, A.G Irwin
St. George’s Hospital, London, UK

CASE REPORT: A diagnostic challenge of a rare case of perirenal extramedullary haematopoiesis – the role of nanocolloid bone marrow imaging
K Alam, M Pandit, B Wee, J.O Brien
City Hospital, Birmingham, UK

99mTc-MDP Bone SPECT/CT in Trauma & Sports Injuries
N Shur, C St, J Connelly, A Desai, S Vijayanathan, G Gnanasegaran
Guy’s & St Thomas’ Hospital NHS Trust, London, UK

Extending the technologist role in initiating plain radiographs and SPECT/CT at bone scintigraphy
K Jandu, R Harris, A R O’Connor
Nottingham University Hospitals NHS Trust, UK

Interfering PETs and the importance of SeHCAT background
LA Holmes, DA Pearce, L Sanders
Queen Alexandra Hospital, Portsmouth, UK

"Cr (EDTA) Glomerular Filtration Rate (GFR) studies: Is it necessary to consider residual activity?
K Lee, R Penny, J Cullis, N Williams
University Hospital Coventry and Warwickshire, UK

The feasibility and appeal of a solely e-based module to develop new skills & knowledge for non-medical healthcare practitioners
P Delf
University of Portsmouth, Hampshire, UK

Optimisation of Scatter Correction and the Addition of Time of Flight Improves Uniformity in Large PET Phantom Studies
G Pawson, I.S Armstrong, P Hogg
Central Manchester Foundation Trust,
University of Salford, UK

A movement correction strategy for static images using dynamic acquisition and registration software
L Lovell, J Wright, J Robinson, R Staff
Nuclear Medicine, Aberdeen UK

Accuracy of Glomerular Filtration Rate calculation from variable blood sampling frequency
A Nunes, M Lugman, E O’Mahoney, M Newell, H Jan
Barts Health NHS Trust, London, UK

In-house preparation and clinical validation of "In-DTPA for oral use in whole gut transit studies
K Solanki, A Wong, W Oware, C Solanki
Addenbrookes Hospital, Cambridge, UK

A review of the impact of SPECT/CT introduction to a nuclear medicine clinic and the learning outcomes
R Harris, K Jandu, C Kalirai
Nottingham University Hospitals NHS Trust, UK

111In-DTPA for oral use in whole gut transit studies
K Solanki, A Wong, W Oware, C Solanki
Addenbrookes Hospital, Cambridge, UK

The importance of patient positioning with IGSPECT™
A. Paramithas, A.G Irwin
St. George’s Hospital, London, UK

In- house preparation and clinical validation of “In-DTPA for oral use in whole gut transit studies
K Solanki, A Wong, W Oware, C Solanki
Addenbrookes Hospital, Cambridge, UK

A review of the impact of SPECT/CT introduction to a nuclear medicine clinic and the learning outcomes
R Harris, K Jandu, C Kalirai
Nottingham University Hospitals NHS Trust, UK

Clinical Practitioners Posters

Accuracy of single sample techniques for assessment of Glomerular Filtration Rate (GFR) and their dependence on sampling time, renal function and extracellular fluid volume (ECFV)
F Wickham, H McMeekin, M Burniston
Royal Free London NHS Trust, UK

Comparison of two methods for labelling white cells with 111In-oiline
E Papadopoulos, GA Wright, G Avery
Hull and East Yorkshire Hospitals NHS Trust, UK

MAG3 renography revisited
P. S Cosgriff, M Aslam
United Lincolnshire Hospitals, Boston, UK

Extending the technologist role in initiating plain radiographs and SPECT/CT at bone scintigraphy
K Jandu, R Harris, A R O’Connor
Nottingham University Hospitals NHS Trust, UK

Interfering PETs and the importance of SeHCAT background
LA Holmes, DA Pearce, L Sanders
Queen Alexandra Hospital, Portsmouth, UK

"Cr (EDTA) Glomerular Filtration Rate (GFR) studies: Is it necessary to consider residual activity?
K Lee, R Penny, J Cullis, N Williams
University Hospital Coventry and Warwickshire, UK

The feasibility and appeal of a solely e-based module to develop new skills & knowledge for non-medical healthcare practitioners
P Delf
University of Portsmouth, Hampshire, UK

Optimisation of Scatter Correction and the Addition of Time of Flight Improves Uniformity in Large PET Phantom Studies
G Pawson, I.S Armstrong, P Hogg
Central Manchester Foundation Trust,
University of Salford, UK

A movement correction strategy for static images using dynamic acquisition and registration software
L Lovell, J Wright, J Robinson, R Staff
Nuclear Medicine, Aberdeen UK

Accuracy of Glomerular Filtration Rate calculation from variable blood sampling frequency
A Nunes, M Lugman, E O’Mahoney, M Newell, H Jan
Barts Health NHS Trust, London, UK

In-house preparation and clinical validation of "In-DTPA for oral use in whole gut transit studies
K Solanki, A Wong, W Oware, C Solanki
Addenbrookes Hospital, Cambridge, UK

A review of the impact of SPECT/CT introduction to a nuclear medicine clinic and the learning outcomes
R Harris, K Jandu, C Kalirai
Nottingham University Hospitals NHS Trust, UK

Clinical Practitioners Posters

Accuracy of single sample techniques for assessment of Glomerular Filtration Rate (GFR) and their dependence on sampling time, renal function and extracellular fluid volume (ECFV)
F Wickham, H McMeekin, M Burniston
Royal Free London NHS Trust, UK

Comparison of two methods for labelling white cells with 111In-oiline
E Papadopoulos, GA Wright, G Avery
Hull and East Yorkshire Hospitals NHS Trust, UK

MAG3 renography revisited
P. S Cosgriff, M Aslam
United Lincolnshire Hospitals, Boston, UK

Extending the technologist role in initiating plain radiographs and SPECT/CT at bone scintigraphy
K Jandu, R Harris, A R O’Connor
Nottingham University Hospitals NHS Trust, UK

Interfering PETs and the importance of SeHCAT background
LA Holmes, DA Pearce, L Sanders
Queen Alexandra Hospital, Portsmouth, UK

"Cr (EDTA) Glomerular Filtration Rate (GFR) studies: Is it necessary to consider residual activity?
K Lee, R Penny, J Cullis, N Williams
University Hospital Coventry and Warwickshire, UK

The feasibility and appeal of a solely e-based module to develop new skills & knowledge for non-medical healthcare practitioners
P Delf
University of Portsmouth, Hampshire, UK

Optimisation of Scatter Correction and the Addition of Time of Flight Improves Uniformity in Large PET Phantom Studies
G Pawson, I.S Armstrong, P Hogg
Central Manchester Foundation Trust,
University of Salford, UK

A movement correction strategy for static images using dynamic acquisition and registration software
L Lovell, J Wright, J Robinson, R Staff
Nuclear Medicine, Aberdeen UK

Accuracy of Glomerular Filtration Rate calculation from variable blood sampling frequency
A Nunes, M Lugman, E O’Mahoney, M Newell, H Jan
Barts Health NHS Trust, London, UK

In-house preparation and clinical validation of "In-DTPA for oral use in whole gut transit studies
K Solanki, A Wong, W Oware, C Solanki
Addenbrookes Hospital, Cambridge, UK

A review of the impact of SPECT/CT introduction to a nuclear medicine clinic and the learning outcomes
R Harris, K Jandu, C Kalirai
Nottingham University Hospitals NHS Trust, UK
Finding your way to the Brighton Centre

How to get there

The Brighton Centre is located on the seafront, on Kings Road, between The Grand Hotel and the Odeon cinema.

Brighton Centre
King’s Road
Brighton
BN1 2GR

By Air

The nearest airport is London Gatwick, 30 minutes away by train. Heathrow airport is 90 minutes by car, coach or taxi.

Parking

There are three NCP car parks located behind the Brighton Centre (one of which serves Churchill Square shopping centre and is the easiest to get in and out of). There are also disabled parking bays at the top of nearby Cannon place where you can park for free with a blue badge, and which are just a five-minute walk from the centre.

Please visit the PET website to see preferential delegate and exhibitor rates for the Regency Square car park.

Public Transportation

The nearest British Rail station is Brighton. It is a ten minute walk from the train station but there is a bus stop on route X11 directly outside the centre.
Our thanks to the following companies for supporting our meeting.

<table>
<thead>
<tr>
<th>Company</th>
<th>Stand no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alliance Medical</td>
<td>8</td>
</tr>
<tr>
<td>Americare</td>
<td>4</td>
</tr>
<tr>
<td>Aquila</td>
<td>6</td>
</tr>
<tr>
<td>Ashby GB</td>
<td>19</td>
</tr>
<tr>
<td>Bartec</td>
<td>28</td>
</tr>
<tr>
<td>Bayer</td>
<td>3b</td>
</tr>
<tr>
<td>BNMS</td>
<td>29</td>
</tr>
<tr>
<td>Bright Technologies</td>
<td>21</td>
</tr>
<tr>
<td>College of Radiographers</td>
<td>5</td>
</tr>
<tr>
<td>Coviden</td>
<td>20</td>
</tr>
<tr>
<td>Diagnostic Imaging</td>
<td>22</td>
</tr>
<tr>
<td>Endocyte, Inc</td>
<td>13</td>
</tr>
<tr>
<td>Ergal</td>
<td>27</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>24</td>
</tr>
<tr>
<td>Hermes</td>
<td>10</td>
</tr>
<tr>
<td>IBA Molecular</td>
<td>11</td>
</tr>
<tr>
<td>Imaging Equipment</td>
<td>26</td>
</tr>
<tr>
<td>Immunomedics</td>
<td>16</td>
</tr>
<tr>
<td>InHealth</td>
<td>25</td>
</tr>
<tr>
<td>Lablogic/Southern Scientific</td>
<td>7</td>
</tr>
<tr>
<td>Lilly UK</td>
<td>14</td>
</tr>
<tr>
<td>Link Medical</td>
<td>18</td>
</tr>
<tr>
<td>Mirada Medical</td>
<td>12</td>
</tr>
<tr>
<td>Oncology Imaging Systems</td>
<td>15</td>
</tr>
<tr>
<td>ONET Technologies</td>
<td>17</td>
</tr>
<tr>
<td>Philips Healthcare</td>
<td>1</td>
</tr>
<tr>
<td>Raytest</td>
<td>3</td>
</tr>
<tr>
<td>Siemens</td>
<td>23</td>
</tr>
<tr>
<td>Sirtex</td>
<td>3a</td>
</tr>
</tbody>
</table>

Exhibiting companies and exhibition floor plan

[Exhibition floor plan image]
Stand No. 8
Alliance Medical is the leading provider of independent imaging services including PET-CT, MRI, CT and X-ray and Ultrasound. Commanding a large mobile fleet and many fixed site partnerships, all supported by an extensive team of highly skilled Radiographers. Alliance Medical provide PET imaging services that include; a mobile PET service, fully managed PET-CT static facilities and radiopharmaceutical supply.

Alliance Medical have operated the DoH NHS PET-CT North Contract for the last five years;

*Providing patients with rapid access to local services
* Ensuring the best possible care
* Clinical reporting by NHS specialties
* Seamless integration with existing services

If you have any questions about a PET imaging service and the different options for gaining access to PET, please visit the Alliance Medical stand to talk to one of our representatives or to pick up a brochure. Contact: Tel: 01926 482222 or email: info@alliancemedical.co.uk. Alternatively, you can visit our website at www.alliancemedical.co.uk.

Stand No. 4
Amercare have been the leading UK manufacturers of Isolators for all Radiopharmacy and Pharmacy applications for over 20 years. We design and manufacture isolators for Nuclear Medicine applications such as Technetium Dispensing and Blood Cell labelling plus specialist isolators for Iodine, PET, Gallium etc. We also provide servicing, validation and spares support for all our isolators. Amercare also manufacture the Amercare Automated Dose Dispenser for safe dispensing of highly active isotopes into syringes or bottles. We also supply isolators for non-radioactive applications such as Chemotherapy, CISAS, TPN and Sterility testing. Contact: Graham Wilson, Tel: 01844 261244 Email: g-wilson@amercare.co.uk www.amercare.co.uk

Stand No. 6
Aquila team has a total of over 200 combined years of experience in the nuclear medicine industry which includes the specialist areas of containment, shielded facilities, remote handling and packaging for radioisotopes. Our engineers have been involved in projects from the design concept right through to manufacturing, testing, installation and commissioning at our clients’ sites. Clients engage with Aquila at different stages in the delivery process, but we like to get involved as early as possible so that we can share best industry practice from the start, saving time, money and delivering exactly to our clients’ requirements. Contact: Dave Myers dmyers@aquilaeurope.eu Tel: 01962 717015 www.aquilaeurope.eu

Stand No. 5
College of Radiographers is committed to developing and promoting the science and practice of medical imaging and radiation therapy. We are the unified voice of radiographers and associated practitioners in clinical practice, education and research and develop and promote policy on current and emerging educational, professional and workforce issues related to nuclear medicine. We provide our members with a range of services including workplace and employment representation, a range of publications including a quarterly peer review journal and online continuing education resources. We welcome visitors to our stand where our representatives will be on hand to discuss a wide range of topics, including regulation, workforce shortages and development, education and training, commission professional development, etc. So, please visit us – members and non-members are all very welcome.

Stand No. 28
Bartec specialises in the supply, delivery, installation and support of Nuclear Medicine equipment and accessories including radiation monitoring, protection and decontamination products. Bartec’s partners in the UK are: Mediso imaging systems, Biodex Medical Systems for Nuclear Medicine Accessories, Data Spectrum Corporation for Specialist Imaging Phenoms and Eckert & Ziegler for Calibration sources. In addition Bartec provides refurbished Gamma Camera systems primarily to the Veterinary market. www.bartectechnologies.com and www.mediso.hu

Stand No. 19
Ashby Gorman Baker is the largest independent nuclear medicine service organisation in Europe. We specialise in the maintenance and repair of many different Gamma Camera systems from a variety of manufacturers. We have offices in several European Countries with our Headquarters and main training centre being based here in the UK. We are very proud of the reputation we have earned for providing excellent, professional and totally customer focused service to our customers, which is cost-effective and of the highest possible quality. We are pleased to have this opportunity to support the PET and look forward to welcoming you to our stand. Tel 01923 400343 Tel (Belgium): + 32 (0) 9 296 23 05 www.ashbygb.com

Stand No. 21
Bright Technologies Ltd, often known as Bri Tec, has a renowned reputation for its expertise in Radiation Protection, Radioactive Material Handling, Shielding, Radio-Pharmaceutical Q.C., and MRI Accessories. A key feature of Bri Tec is our Sheffield based in-house design and manufacturing facility. We have wide ranging experience of working with many NHS Trusts, Further Education Institutes and commercial companies. Our in-house design team and production facility allows us to take your ideas and designs, develop them and, put them into production. This versatility allows Bri Tec to undertake both low and high volume production runs. In addition we are able to bespoke manufacture room installations so that the room space is optimally utilised in terms of both space and user friendliness. What do we mean by this? The installation fits both your requirements and the room – not the other way round! Contact us: Bri-Tec House 1 Holbrook Commerce Park, Holbrook Close, Sheffield S20 3FJ, Tel: +44 (0)114 2511215 Fax: +44 (0)114 2511216 E-Mail: stephen-britec@btconnect.com Web: www.britec.net

Stand No. 22
Diagnostic Imaging Limited is the exclusive supplier of SmartVent, the best selling radioaerosol delivery system in the UK. We also supply a wide range of radiopharmaceuticals and radioisotopes from a number of manufacturers, plus the exciting new range of gamma cameras from DDD. Please visit our stand to discuss with us how we can help you.

Stand No.13
Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company’s SMDCs actively target receptors (e.g. folate receptors and PSMA) that are over-expressed in diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses these targets and who are therefore more likely to benefit from treatment.

Stand No. 27
Enrigal is the leading provider in the United Kingdom and Ireland of radiopharmaceuticals for Positron Emission Tomography. Our business is built around the principles of quality and reliability. Recognising the importance of service continuity, we aim to deliver the most reliable and leading quality radiopharmaceuticals. Our RPU facilities are all designed to optimise product quality, production capacity and reliability.

Our commitment to quality and reliability is demonstrated by our investment in the establishment of an unrivalled network of 4 GMP-licensed production facilities in the UK and Ireland. These are in Dublin, Klee, Preston and Sutton (Surrey). Each of these units has a minimum of 2 clean rooms for routine production of radiopharmaceuticals, providing a unique back up capability. In addition to FDG, Enrigal currently manufactures both F-Choline and Sodium Fluoride. Other tracer are under development.
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Stand No. 11
IBA Group develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy.

In 2012 IBA and SK Capital Partners, a U.S. based private investment firm, announced that they have entered into an agreement to create IBA Molecular Imaging. HERMES maintains image data integrity across all vendor platforms, providing you with the freedom of choice for new camera purchases. Hermes Medical Solutions Ltd Grove House, 2 Orange Street, London, WC2H 7DF Phone: 020 3178 8980, Fax: 020 3178 6101 E-mail: info@hermesmedical.com Website: www.hermesmedical.com Contact: Jan Bertling CEO

Stand No. 16
Immunomedics GmbH is a subsidiary of Immunomedics, Inc., a New Jersey based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The company has developed a number of advanced proprietary technologies to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes or chemotherapeutics, in each case to create highly targeted agents. The European headquarters and real-time monitoring of cancer and other major diseases. The company is dedicated to connecting nuclear medicine in the UK and Ireland to the future of nuclear medicine, as a whole, and IBA Molecular Imaging, in particular. We will endeavour to continue to provide patients with early detection, better characterization and real-time monitoring of cancer and other major diseases, with the continuing growth and development of our radiopharmaceutical business. We believe we can build upon a solid business foundation by leveraging our unique strengths and capabilities to drive future value by enhancing its manufacturing assets, expanding its geographic coverage, and investing in new product development.

Contact: Mike Ward, 07973 444394 mike.ward@iba-group.com Tel: 01483 301638 www.ibamolecular.com

Stand No. 25
InHealth Limited is the UK’s leading provider of diagnostic and imaging services. It has delivered over 800 contracts for NHS and private providers including PET-CT, MRI, X-Ray, DXA, ultrasound, mammography, echocardiography, interventional cardiology, ENT and audiology. InHealth delivers the South of England PETCT Service on behalf of the NHS. InHealth was the first UK provider of PET scanning services outside the NHS. It now operates a number of static and mobile PET-CT facilities including the UK’s first independent PET-CT Centre with a Cyclotron. For more information contact info@inhealthgroup.com or 0845 045 3666. For information on the South of England PET-CT Service please contact 0845 600 2983 or email inl.petctsouth.nhs.net www.inhealthgroup.com

Stand No. 26
Imaging Equipment Ltd IEL is the largest independent distributor of specialist Nuclear Medicine products in the UK and Ireland. Our wide portfolio that includes Radiopharmaceuticals, PET injectors, Radionuclide therapy, extensive shielding and radiation protection; from some of the world’s most respected manufacturers including ROTOP, Tema, Eckert & Ziegler, Von Galningen and Fluke, enables us to meet our customers’ requirements and to build packages that meet both technical specification and budgetary demands. Our team of specialist Nuclear Medicine sales consultants, supported by a dedicated and experienced technical team, provide a personal, high-quality service to customers across the UK and Ireland. We offer expert product demonstrations and well-supported trial periods that enable customers to make detailed technical decisions. Our sales consultants continue to take a leading role in helping to disseminate knowledge and research related to some of the most cutting-edge nuclear imaging techniques, and in doing so have supported departments and patients alike.

IEL is dedicated to connecting nuclear medicine in the UK and Ireland to the future of nuclear medicine, as a whole, and IBA Molecular Imaging, in particular. We will endeavour to continue to provide patients with early detection, better characterization and real-time monitoring of cancer and other major diseases, with the continuing growth and development of our radiopharmaceutical business. We believe we can build upon a solid business foundation by leveraging our unique strengths and capabilities to drive future value by enhancing its manufacturing assets, expanding its geographic coverage, and investing in new product development.

Contact: Mike Ward, 07973 444394 mike.ward@iba-group.com Tel: 01483 301638 www.ibamolecular.com

Stand No. 25
InHealth Limited is the UK’s leading provider of diagnostic and imaging services. It has delivered over 800 contracts for NHS and private providers including PET-CT, MRI, X-Ray, DXA, ultrasound, mammography, echocardiography, interventional cardiology, ENT and audiology. InHealth delivers the South of England PETCT Service on behalf of the NHS. InHealth was the first UK provider of PET scanning services outside the NHS. It now operates a number of static and mobile PET-CT facilities including the UK’s first independent PET-CT Centre with a Cyclotron. For more information contact info@inhealthgroup.com or 0845 045 3666. For information on the South of England PET-CT Service please contact 0845 600 2983 or email inl.petctsouth.nhs.net www.inhealthgroup.com

Stand No. 7
Labmed is the leading manufacturer and supplier of innovative Quality Control equipment and Laboratory Information Management Systems (LIMS) for PET and SPECT applications. We can source, supply, install and validate the complete range of imaging needs. Whether it be longitudinal tracking in Oncology, database design to differentiate Alzheimer’s Disease & Fronto - Temporal Dementia, advances in cardiac PET imaging or bridging Radiology, Nuclear Medicine & PET, HERMES is leading the way. HERMES is a vendor-neutral, uniform processing platform for Nuclear Medicine, PET-CT/MR and Multi-Modality imaging. HERMES maintains image data integrity across all vendor platforms, providing you with the freedom of choice for new camera purchases.

Stand No. 10
Hermes Medical Solutions was established in 1976 in Stockholm, Sweden, and is a leading innovator in medical imaging hardware/software products for health care facilities worldwide. HERMES delivers a wide range of medical imaging solutions to optimize hospital workflow for your local requirements.

HERMES software - designed for your clinical imaging needs: Fighting illness & disease requires state-of-the-art imaging modalities & software in order to diagnose accurately, stage disease appropriately & select the best treatment available. HERMES partners with the best institutions globally to continually deliver customized diagnostic software packages to meet your ever-changing medical
equipment needed in order to operate your QC facility. LabLogic’s products and services allow you to establish and operate your research or routine PET facility efficiently and with confidence. Our state of the art equipment and cutting edge software is backed by full operations training and validation documentation to ensure GMP compliance. In addition LabLogic is the only supplier of PETra, a dedicated PET Laboratory Information Management System (LIMS). PETra manages the complete process in PET facilities, including batch records, inventory, SOPs, equipment maintenance logs, trending, label design, etc. For more information please visit us on our stand

Contact: LabLogic Systems Limited, Paradigm House, 3 Melbourne Avenue, Broomhill, Sheffield, S10 2QJ.
Tel: 00 44 114 266 7267
Robert Woodcock
E-mail: rwoodcock@lablogic.com

Stand No. 18
Link Medical Limited are specialists in the provision of imaging software for Nuclear Medicine and Radiology departments. Many UK and customers use Link Medical to provide solutions for Networking, PACS Connectivity, Image Fusion, Image Processing and many other applications. More recently, Link Medical have obtained a Wholesale Dealers Licence from the MHRA allowing the distribution of Radiopharmaceuticals. We now supply an increasing number of UK radiopharmacies with products from Medi-Radiopharma and IDB, including the recently licensed Med-Exometazime HMPAO for brain and infection imaging. We will be delighted to discuss your requirements at PET 2013 in Brighton on our stand.

Contact: Peter Dobson, Link Medical Ltd,
Tel: +44 (0)118 932 6850
Mobile: +44 (0)7527 844022
peter@linkmed.co.uk

Stand No. 12
Mirada Medical is an internationally recognized brand developing medical imaging. The company produces technologically advanced, vendor neutral, software applications, which are used across nuclear medicine, diagnostic radiology, radiation oncology and elsewhere. X3D, Mirada Medical’s Image review software, offers validated, industry-leading deformable registration to allow clinicians to fuse and view multi-modalities including PET-CT/MRI/SPECT. X3D also facilitates time saving RECIST and volumetric measurements through specialized tools, including automatic CT lesion. In 2010, Mirada introduced a powerful range of software tools built specifically for Radiation Oncology. These tools incorporate Mirada’s proven fusion technology, to support dose warping and summation, atlas based auto-contouring, deformable fusion of multi-sequence MRI, PET and SPECT, and single click contour warping for rapid adaptive re-planning. In addition, powerful imaging solutions have been recently introduced by Mirada to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings. Visit our website www.mirada-medical.com

Stand No. 13
ONET Technologies UK Ltd provides a complete design and build service for the provision of radiopharmaceutical process equipment ranging from research hot cells and cyclotron support equipment to GMP production facilities for producing technetium generator, iodine seeds, and radiopharmaceuticals for PET and SPECT.

Visit: www.onet-technologies-UK.com
Tel: 01489 897 315

Stand No. 1
Philips Healthcare - Transforming care, together. Philips is a diversified health and well-being company and a world leader in healthcare, lifestyle and lighting. Our vision is to make the world healthier and more sustainable through meaningful innovation. We develop innovative healthcare solutions across care, in partnership with clinicians and our customers to improve patient outcomes, provide better value, and expand access to care. As part of this mission we are committed to fueling a revolution in imaging solutions, dedicated to deliver greater collaboration and integration, increased patient focus, and improved economic value. We provide advanced imaging technologies you can count on to make confident and informed clinical decisions, while providing more efficient, more personalised care for patients.

The Philips IntelliSpace Portal is an excellent example of how advanced imaging solutions can deliver greater collaboration and integration. Now with access to molecular imaging applications, the Philips IntelliSpace Portal enables clinicians to process, analyse, share and review images from all molecular imaging modalities including SPECT, SPECT/CT, PET-CT and PET/MR anytime, anywhere, anyhow.

And, surprisingly compact given its capabilities, at the heart of BrightView XCT is the unique integration of BrightView with advanced Philips flat-panel X-ray technology. Substantial clinical advantages include co-planar SPECT and CT, flexible CT breathing protocols optimised for localisation and attenuation correction, and high resolution at low CT dose levels. Contact us on 01483 298543 or visit www.philips.com/imaging2.0

Stand No. 3
Raytest is a world leader in the design and manufacture of specialised systems for the measurement and detection of radiation, supplying rugged, reliable, precision instruments to radiochemists in PET, nuclear medicine, and pharmaceutical research. The Raytest product range includes:

Synthesis systems for automated radio labelling and chromatography.

Laboratory instrumentation, including HPLC, GC, TLC and a multichannel analyser.

A LIMS system, providing a single consolidated report for all QC tests.

A range of preclinical scanners including PET-CT, PET/MR and CT

Whenever you need accurate, precise, reliable radiation measurement, Raytest has a solution. Please visit the raytest booth to discuss your specific requirements.

Stand No. 23
Siemens offers a wide and extensive range of Molecular Imaging solutions, including the Symbia S, a flexible, large field of view dual head system, with the option for fully automated daily quality control measurements; and the Symbia T range, a family of SPECT/CT systems offering diagnostic CT performance with multi-slice technology. For PET investigations, the Biograph mCT system, offers up to 128-slice CT technology, combined with PET HD algorithms and time-of-flight capabilities to afford unsurpassed image quality. For image handling and processing, a thin client solution meets the needs of either the SPECT or PET user. In addition PETNET Solutions, part of Siemens Molecular Imaging supply MetaTrace FDG Fluodeoxiglycose [18F] and other [18F] PET tracers to the UK from their 2 cyclotron facilities in Mount Vernon and Nottingham.

For further technical information please contact: Siemens Healthcare
Sir William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD
Tel: 01276 696439 Fax: 01276 696466
### Stand No. 3a
**Sirtex Medical Europe GmbH** is a wholly-owned subsidiary of Sirtex Medical Limited, a publicly-listed company on the Australian Securities Exchange engaged in the field of liver-directed therapies for oncology. Our innovative technology, SIR-Spheres® microspheres, was approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark and for the treatment of colorectal cancer liver metastases in combination with FUDR intra-arterial chemotherapy by the US Food & Drug Administration. SIR-Spheres microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma at over 100 institutions throughout Europe. For more information, please contact Trish O’Neill (National Sales Manager UK & Ireland) on toneill@sirtex-europe.com 07595154898.

®SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

### Stand No. 7
**Southern Scientific** is based in Henfield, West Sussex, and has been serving the medical and nuclear market for 25 years. Our customers include hospitals, nuclear power, processing and research sites, industry and the Ministry of Defence. We supply a wide range of Radiation Protection equipment including our Radhound range of Contamination monitors, alongside Scintillation, Contamination and GM probes to suit all applications. Southern Scientific also supplies a wide range of Capintec products, as well as effective decontamination agents and Amici Lung Ventilation equipment. Our talented team of sales, service and applications specialists offer comprehensive product support. Southern Scientific Ltd. is an ISO-9001/2008 and ISO-13485 company, and all our products are CE marked. Please visit our stand to find out more about our range of products and services.

### Stand No. 3b
**Bayer HealthCare’s Radiology & Interventional.** In our organisation, you will find a single source for radiology, interventional, and equipment support services - a trusted leader in patient care and practice solutions. Meet your goals with a comprehensive portfolio of products including the Medrad® Intego™ PET Infusion System. The Intego™ system infuses doses on demand from a multi-dose vial providing you with greater flexibility, enhanced workflow, added protection and more accurate, repeatable patient specific dosing. Our comprehensive solutions and focus on value are designed to simplify workflow and improve operational outcomes. Please come to the Bayer stand to see the Medrad® Intego™ and hear how the system will help you in your busy department. Contact the Customer Service team on Tel: 01635 563999
BNMS membership application form

Application for Full Membership □  Associate Membership □ (please tick)

Surname:_________________ Forename ___________________ Title ____________
Hospital/Institute __________________________________________________________
Work address ______________________________________________________________
________________________________________________________________________
Postcode __________________________
Tel: __________________ Fax: __________________
Email: __________________ (print carefully)
Home Address ______________________________________________________________
________________________________________________________________________
Postcode __________________________

Two sponsoring members: for individuals applying for full membership

Member's name __________________________
Signature __________________________
Member's name __________________________
Signature __________________________

Please send all correspondence to my WORK / HOME address (delete as appropriate)

Position/Qualifications: ______________________________________________________
Duration and extent of nuclear medicine responsibilities __________________________

Specialty: (For our database please tick ONE category)

Clinician □  Radiographer □  Technologist □
Medical Physicist □  Radiologist □  Veterinary Surgeon □
Nuclear Physician □  Radiopharmacist □
Nurse □  Radiotherapist □

Are you happy for us to include your details in our on-line Members Directory? Yes □ No □
Are you happy for us to forward your details to third parties (e.g. manufacturers)? Yes □ No □

Note: If you do not answer the above questions we will assume a ‘Yes’ response to both.
Annual Membership | UK | Overseas
--- | --- | ---
Full Member | £132.00 | £172.00
Full Member – reduced rate | £108.00 | £122.00
Associate Rate | £60.00 | £87.00

The reduced rate is available according to grade of employment as follows:

(a) Medical staff, etc. – not holding a consultant or equivalent post
(b) Clinical scientist – below NHS B17 or equivalent
(c) Academic staff – below Senior Lecturer or equivalent research staff grade
(d) Pharmacist – below NHS grade F or equivalent
(e) Technologists/Radiographers/Nurses – any grade

The reduced rate for categories (a) to (d) should be claimed by submitting a signed declaration upon application to join the Society.

I enclose payment of £ _________ (UK member)

or £ _________ (Overseas member)

Applications must be accompanied by cheque, bank transfer, money order or credit card details. Alternatively the Society operates a monthly direct debit system. Please request a form from staff on the Registration Desk. Payments must be made in sterling drawn on a UK bank made payable to British Nuclear Medicine Society and should be sent with this form to:

British Nuclear Medicine Society
Regent House, 291 Kirkdale, London SE26 4QD

Credit card payments

I authorise you to debit my ViSA/Mastercard/American Express/Switch account with the amount of:

£ _________

Card number _______________________

Expiry date ______________________ Issue no. ______________________

Security code (last 3 digits on reverse of card) ______________________

Signature ______________________ Date ______________________

Methods of payment